On this page
Quick Reference
Overview and Recommendations
Background
- •Define SIADH as a state of caused by non-osmotic AVP secretion.
- •Identify common triggers including , traumatic brain injury, stroke, and pneumonia.
- •Review medication history for offending agents such as , carbamazepine, cyclophosphamide, and NSAIDs.
- •Recognize that the pathophysiology involves constitutive activation of channels in the renal collecting ducts.
- •Distinguish from (CSWS), which presents with hypovolemia and high urine output.
Evaluation
- •Confirm hypotonic hyponatremia with serum sodium <135 mEq/L and serum osmolality <275 mOsm/kg.
- •Document inappropriate urine concentration with urine osmolality >100 mOsm/kg.
- •Obtain spot urine sodium; levels >30 mmol/L suggest SIADH in the setting of normal salt intake.
- •Rule out and by checking TSH and morning cortisol levels.
- •Assess clinical volume status to ensure the patient is euvolemic (absence of edema, ascites, or orthostatic hypotension).
- •Calculate fractional excretion of uric acid (FEUrate); a value >12% strongly supports SIADH.
- •Order chest X-ray or CT to screen for occult pulmonary malignancy or infection.
Management
- •Administer Hypertonic Saline (3% NaCl) 100–150 mL IV bolus over 20 minutes for severe symptoms (seizures, coma).
- •Limit sodium correction to <10 mmol/L in the first 24 hours to avoid .
- •Initiate fluid restriction to 800–1000 mL/day as first-line therapy for asymptomatic or mild cases.
- •Consider Tolvaptan 7.5 mg to 15 mg orally once daily for patients refractory to fluid restriction.
- •Administer oral urea 15–30 g daily to induce osmotic diuresis in chronic or oncology-related cases.
- •Utilize loop diuretics (e.g., Furosemide 20 mg) combined with salt tablets to increase solute-free water clearance.
- •Discontinue any suspected offending medications immediately.
- •Monitor serum sodium every 4–6 hours during the active correction phase.
Board Review — High Yield
- •Small Cell Lung Cancer — The classic paraneoplastic cause of ectopic ADH production.
- •Euvolemia — The essential clinical volume status required for SIADH diagnosis.
- •Osmotic Demyelination Syndrome — The catastrophic neurological consequence of correcting sodium too rapidly, often affecting the pons.
- •Urine Osmolality >100 mOsm/kg — The hallmark of 'inappropriate' concentration in the face of serum hypotonicity.
- •Hypouricemia — Low serum uric acid (<4 mg/dL) is common due to increased urate clearance.
- •V2 Receptor — The specific vasopressin receptor in the kidney targeted by AVP and antagonized by vaptans.
- •Copeptin — A stable surrogate biomarker for AVP that is elevated in SIADH.
- •Reset Osmostat — A variant of SIADH where ADH is regulated but at a lower osmotic threshold.
Deep Dive — Evidence Details
Definition and Components
- ▸SIADH is defined by hypotonic hyponatremia (serum sodium <135 mEq/L) and inappropriately concentrated urine (urine osmolality >100 mOsm/kg) in a clinically euvolemic patient.
- ▸The condition results from the non-suppressible release of ADH, which acts on V2 receptors in the distal renal tubules to cause water retention.
- ▸Diagnosis requires the exclusion of renal failure, adrenal insufficiency (hypocortisolism), and hypothyroidism.
The Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH), also referred to as the Syndrome of Inappropriate Antidiuresis (SIAD), is a clinical disorder of sodium and water balance [4]D[7]C. It is characterized by the non-physiological secretion of arginine vasopressin (AVP), also known as antidiuretic hormone (ADH), despite a low serum osmolality and a normal or increased circulating blood volume [7]C[11]C. This inappropriate secretion leads to excessive water reabsorption in the distal renal tubules via the type 2 vasopressin receptor, resulting in dilutional hyponatremia and impaired urinary dilution [5]D[7]C.
Historical and Physiological Context
First described by Schwartz and Bartter in 1957, SIADH is the most common cause of euvolemic hyponatremia, accounting for more than 35% of cases in hospitalized patients [5]D[7]C. In a healthy physiological state, ADH secretion is suppressed when serum osmolality falls below a certain threshold (typically <280 mOsm/kg). In SIADH, this regulatory mechanism fails, and ADH continues to be secreted, preventing the kidneys from excreting excess water [13]D[25]C. This results in a state of relative water excess rather than a total body sodium deficiency [5]D.
Diagnostic Components
The diagnosis of SIADH is based on a set of clinical and laboratory criteria. It is a diagnosis of exclusion, requiring the absence of renal, adrenal, or thyroid dysfunction [16]C[22]D. The fundamental components include:
- Hypotonic Hyponatremia: Serum sodium <135 mEq/L and serum osmolality <275 mOsm/kg [4]D[5]D[11]C.
- Inappropriate Urine Concentration: Urine osmolality typically >100 mOsm/kg despite low serum osmolality [8]C[11]C.
- Elevated Urine Sodium: Urine sodium concentration is generally >30 mmol/L with normal dietary salt intake [8]C[17]C.
- Clinical Euvolemia: Absence of clinical signs of volume depletion (e.g., orthostatic hypotension, dry mucous membranes) or volume excess (e.g., edema, ascites) [7]C[11]C.
- Exclusion of Other Causes: Normal thyroid function (TSH) and adrenal function (cortisol), and no recent use of diuretics [4]D[16]C.
Etiology and Associated Conditions
SIADH is associated with a wide array of underlying pathologies, ranging from malignancies to central nervous system (CNS) disorders and medications. The following table lists the known causes identified in clinical literature [1-27].
| Category | Specific Causes and Conditions |
|---|---|
| Malignancies | Small-cell lung cancer [24]C[27]C, Neuroendocrine prostate cancer [1], Gastric adenocarcinoma [21]C, Hypothalamic lymphoma [25]C, Duodenal gastrinoma [18]C, Typical carcinoid [25]C, Lung adenocarcinoma [6]C |
| CNS Disorders | Traumatic brain injury [8]C, Corpus callosum agenesis [7]C, Giant hypothalamic hamartoma [15]C, Pituitary macroadenoma [18]C[22]D, West Nile Virus encephalitis [20]C, Hashimoto encephalopathy [23]C, Cerebral edema [11]C[13]D |
| Pulmonary | Eosinophilic granulomatosis with polyangiitis (EGPA) [3]C, Pneumonia/Sepsis [11]C |
| Pharmacological | Osimertinib [6]C, Ketamine [9]C, Proton pump inhibitors (PPIs) [26]D, Ibrutinib [22]D |
| Other | Hematopoietic stem cell transplantation [16]C, Ruptured silicone breast implants [12]C, Gastritis [8]C, Heat stroke [18]C |
Clinical Significance
Hyponatremia in SIADH can range from mild and asymptomatic to severe and life-threatening [5]D[10]D. Symptoms often depend on the rapidity of the decline in serum sodium. Acute hyponatremia may lead to cerebral edema, manifesting as seizures, coma, or ataxia [11]C[13]D[19]C. Chronic hyponatremia, even if mild, is associated with cognitive impairment, gait disturbances, and an increased risk of falls and fractures [5]D. In extreme cases, such as serum sodium <105 mmol/L, the risk of osmotic demyelination and permanent neurological damage is significant [14]C.
| Category | Specific Causes and Conditions |
|---|---|
| Malignancies | Small-cell lung cancer, Neuroendocrine prostate cancer, Gastric adenocarcinoma, Hypothalamic lymphoma, Duodenal gastrinoma, Typical carcinoid, Lung adenocarcinoma |
| CNS Disorders | Traumatic brain injury, Corpus callosum agenesis, Giant hypothalamic hamartoma, Pituitary macroadenoma, West Nile Virus encephalitis, Hashimoto encephalopathy, Cerebral edema |
| Pulmonary | Eosinophilic granulomatosis with polyangiitis (EGPA), Pneumonia/Sepsis |
| Pharmacological | Osimertinib, Ketamine, Proton pump inhibitors (PPIs), Ibrutinib |
| Other | Hematopoietic stem cell transplantation, Ruptured silicone breast implants, Gastritis, Heat stroke |
Epidemiology and Risk Factors
- ▸SIADH is the leading cause of hyponatremia in hospitalized patients, representing roughly 33% of all cases.
- ▸Postoperative hyponatremia is a major complication of transsphenoidal surgery, frequently occurring as a delayed event 7–10 days after the procedure.
- ▸Small cell lung cancer and ectopic olfactory neuroblastoma are among the highest-risk malignancies for paraneoplastic SIADH.
The syndrome of inappropriate antidiuretic hormone secretion (SIADH) is the most frequent cause of in clinical practice, accounting for approximately one-third of all cases [53]D. It is particularly prevalent among hospitalized patients, where electrolyte imbalances significantly impact morbidity, mortality, and hospital length of stay [37][39][40].
General Prevalence and Demographics
Hyponatremia is the most common fluid and electrolyte disorder in hospitalized populations [40]. In specific cohorts, such as those with , SIADH is identified as the primary underlying cause of low serum sodium [37]. Advanced age is a significant demographic risk factor; patients >65 years exhibit a higher incidence, often exacerbated by polypharmacy and comorbid conditions [40][41]D. In certain neurosurgical populations, such as those undergoing resection for tuberculum sellae meningiomas, a female predominance (up to 70%) has been observed [32].
Malignancy-Associated Risk
Malignancy is a classic driver of SIADH, often presenting as a . (SCLC) is the most frequently associated solid tumor, with hyponatremia occurring in up to 18.9% of patients [56]D. Across all lung cancer types, the prevalence of hyponatremia averages 24.5%, though reported ranges vary widely from 3% to 94.8% [33].
Recent evidence highlights the risk in rare nasal and paranasal tumors. Olfactory neuroblastoma (ONB) is associated with SIADH in approximately 15.4% of cases [42]D. Notably, "ectopic" ONB (originating outside the olfactory cleft) carries a higher frequency of SIADH compared to orthotopic tumors [29]. Other associated malignancies include neuroendocrine carcinoma, squamous cell carcinoma, and mediastinal neuroblastoma [42]D[52]C.
Neurosurgical and Neurological Risk Factors
Procedures involving the sellar and suprasellar regions carry a high risk of postoperative SIADH due to manipulation of the and hypothalamus [28][36].
- Transsphenoidal Surgery (TSS): The incidence of postoperative hyponatremia following TSS for pituitary adenomas ranges from 9% to 30.7% [28][34].
- Delayed Symptomatic Hyponatremia (DSH): This often occurs after hospital discharge, with an incidence of 14.8%. Symptoms typically manifest approximately 8.6 days post-surgery [47]D.
- Traumatic Brain Injury (TBI): Hyponatremia is a common complication of acute TBI, though specific incidence rates vary based on injury severity [50]D.
- Other Neurological Conditions: SIADH is associated with (aSAH), (NMOSD), and (GBS) [41]D[44]D[46]D. In NMOSD, electrolyte disturbances may overlap with Sjögren's syndrome and renal tubular acidosis [44]D.
Medication-Induced SIADH
Psychotropic medications are among the most common triggers for drug-induced SIADH [53]D. The risk is particularly high in elderly patients initiated on (SSRIs) [40].
Systemic and Genetic Factors
- Infections: SIADH has been documented as a complication of , , and respiratory syncytial virus (RSV) [38][39][41]D.
- Genetic Syndromes: In (PWS), approximately 2.6% of patients experience mild to moderate hyponatremia. Risk factors in this population include excessive fluid intake (EFI), psychotropic use, and desmopressin therapy [54]D.
- Lifestyle/Behavioral: Excessive water intake combined with impaired renal water excretion—potentially influenced by multiple subclinical risk factors—has been hypothesized in high-profile cases of fatal cerebral edema [13]D.
| Malignancy Type | Reported Incidence/Prevalence | Clinical Context |
|---|---|---|
| Small Cell Lung Cancer (SCLC) | Up to 18.9% [56]D | Most common solid tumor association |
| Lung Cancer (All types) | 24.5% (average) [33] | Significant prognostic indicator |
| Olfactory Neuroblastoma (ONB) | 15.4% [42]D | Higher risk in ectopic (eONB) locations [29] |
| Neuroendocrine Carcinoma | ~11.1% [42]D | Nasal/paranasal origin |
| Squamous Cell Carcinoma | ~1.6% [42]D | Nasal/paranasal origin |
| Mediastinal Neuroblastoma | Rare [52]C | Reported in elderly populations |
| Medication Class | Specific Examples | Risk Population |
|---|---|---|
| SSRIs | Fluoxetine, Sertraline | Elderly patients (>65 years) [40][53]D |
| SNRIs | Venlafaxine, Duloxetine | General psychiatric population [53]D |
| Antipsychotics | Haloperidol, Quetiapine | Patients with multiple comorbidities [53]D |
| Anticonvulsants | Carbamazepine, Valproate | Chronic epilepsy management [53]D |
| TKI Inhibitors | Osimertinib | Metastatic EGFR-mutant NSCLC [35]C |
| Other | Mirtazapine | Adult and elderly patients [40] |
| Condition/Procedure | Incidence of Hyponatremia | Key Timing/Factors |
|---|---|---|
| Transsphenoidal Surgery (TSS) | 9% – 30.7% [34] | Primary cause of hospital readmission |
| Delayed Hyponatremia (Post-TSS) | 14.8% [47]D | Peaks at ~8.6 days post-operatively |
| Acute Stroke | Common [37] | Most frequent electrolyte imbalance in stroke |
| Traumatic Brain Injury (TBI) | Variable [50]D | Linked to increased morbidity/mortality |
| NMOSD | ~12% overlap [44]D | Often overlaps with Sjögren's syndrome |
Etiology
- ▸SIADH is primarily caused by non-osmotic AVP release or constitutive V2 receptor activation, leading to impaired free water excretion.
- ▸Small cell lung cancer (SCLC) is the most frequent malignant cause, often presenting as a paraneoplastic syndrome.
- ▸Drug-induced SIADH is highly prevalent in the elderly, with SSRIs and SNRIs being the most common culprits.
The Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH), also referred to as the Syndrome of Inappropriate Antidiuresis (SIAD), results from the non-osmotic release of arginine vasopressin (AVP) [60]D, [62]D. This inappropriate secretion leads to water retention via the activation of renal vasopressin type 2 (V2) receptors and the subsequent upregulation of (AQP2) water channels in the collecting ducts [60]D, [64]D. The etiology of SIADH is diverse and frequently multifactorial, especially in hospitalized patients [62]D, [76]D.
Malignancy
Malignancy is a primary cause of SIADH, often occurring as a due to ectopic AVP production by tumor cells [60]D, [66]C. Small cell lung cancer (SCLC) is the most common malignancy associated with SIADH [57]C, [75]D. The prevalence of hyponatremia in lung cancer patients ranges from 3% to 94.8% [33].
| Malignancy Type | Specific Examples and Notes |
|---|---|
| Lung Cancer | Small cell lung cancer (SCLC) [57]C, [58], [66]C, [71]C; Lung adenocarcinoma [6]C, [35]C. |
| Head and Neck | Ectopic olfactory neuroblastoma [68]C; various head and neck squamous cell carcinomas [60]D, [62]D. |
| Genitourinary | Prostate cancer (reported following high-dose-rate brachytherapy) [73]C. |
| Other | Various neuroendocrine tumors [68]C. |
Central Nervous System Disorders
Any structural, inflammatory, or metabolic insult to the central nervous system (CNS) can disrupt the hypothalamic-pituitary axis, leading to unregulated AVP release [60]D, [73]C.
- Vascular: Ischemic stroke, hemorrhagic stroke, and subarachnoid hemorrhage [60]D, [62]D.
- Trauma: Traumatic brain injury and post-traumatic cerebral venous sinus thrombosis [60]D, [78]C.
- Infection: Meningitis, encephalitis, and brain abscesses [60]D, [62]D.
- Increased Pressure: Raised intracranial pressure from any cause, including cerebral edema [13]D, [67]C, [78]C.
- Other: Neuroleptic malignant syndrome (NMS) [67]C.
Pulmonary Diseases
Non-malignant pulmonary conditions can trigger SIADH through mechanisms involving hypoxia, hypercapnia, or local inflammation affecting thoracic baroreceptors [60]D, [62]D.
- Infections: Bacterial pneumonia, viral pneumonia, and [60]D, [77]C.
- Mechanical: Positive pressure ventilation [60]D.
- Chronic Disease: Acute respiratory failure [60]D.
Drug-Induced SIADH
Medications are a frequent cause of SIADH, particularly in elderly populations [40], [59]D. Drugs may stimulate AVP release, increase the sensitivity of V2 receptors, or act as direct V2 receptor agonists [63]D, [69]D.
| Drug Class | Specific Agents |
|---|---|
| Antidepressants | SSRIs (Escitalopram, Fluoxetine, Paroxetine, Sertraline, Citalopram) [65]C, [70]D, [74]C; SNRIs (Duloxetine, Venlafaxine) [70]D, [72]C; Mirtazapine [40]; Bupropion [70]D. |
| Anticonvulsants | Carbamazepine, Valproate [53]D. |
| Antipsychotics | Quetiapine, Haloperidol [53]D, [65]C. |
| Chemotherapy | Cyclophosphamide, Cisplatin, Ifosfamide, Osimertinib [6]C, [35]C, [53]D, [75]D. |
| Hormonal Analogs | Desmopressin (used for nocturnal polyuria), Oxytocin (used for labor induction) [63]D. |
| Other | NSAIDs, Omeprazole [53]D, [70]D. |
Miscellaneous and Rare Causes
- Hereditary (NSIAD): Nephrogenic Syndrome of Inappropriate Antidiuresis is caused by gain-of-function mutations in the AVPR2 gene, leading to constitutive activation of the V2 receptor despite suppressed AVP levels [60]D, [63]D.
- Postoperative State: SIADH is common after major surgery, including endoscopic skull base surgery and prostate brachytherapy [51]D, [73]C.
- Environmental/Lifestyle: Excessive water intake (water intoxication) combined with impaired renal excretion [13]D, [67]C.
- Inflammatory/Foreign Body: Ruptured silicone breast implants leading to systemic autoinflammatory reactions [12]C.
- Idiopathic: SIADH in the elderly without a clear identifiable cause, often related to age-related changes in osmoregulation [40], [60]D.
| Class | Examples | Mechanism |
|---|---|---|
| SSRIs | Escitalopram, Sertraline | Increased AVP release [65]C, [70]D |
| SNRIs | Duloxetine, Venlafaxine | Increased AVP release [70]D, [72]C |
| Anticonvulsants | Carbamazepine | Increased V2R sensitivity [53]D |
| Cytotoxics | Cyclophosphamide, Osimertinib | Direct AVP stimulation/Ectopic [6]C, [53]D |
| V2R Agonists | Desmopressin, Oxytocin | Direct receptor activation [63]D |
Pathophysiology
- ▸SIADH is driven by non-osmotic AVP secretion or V2 receptor overactivity, leading to AQP2-mediated water reabsorption.
- ▸Euvolemia is maintained by secondary natriuresis and the 'vasopressin escape' mechanism, which downregulates AQP2 to prevent edema.
- ▸Copeptin serves as a stable, equimolar surrogate biomarker for AVP in the assessment of osmoregulatory dysfunction.
The syndrome of inappropriate antidiuretic hormone secretion (SIADH) is a disorder of water balance characterized by the non-physiological release of arginine vasopressin (AVP) or the constitutive activation of its signaling pathways [84]D[86]D. This results in impaired renal water excretion and dilutional hyponatremia despite low plasma osmolality [69]D[90]D.
Molecular Mechanisms of Water Retention
Under normal physiological conditions, the hypothalamic-pituitary axis regulates tonicity by sensing changes via circumventricular organs [85]D[86]D. In SIADH, AVP is secreted independently of osmotic or volume stimuli [86]D. AVP binds to the vasopressin V2 receptor (V2R), a G protein-coupled receptor located on the basolateral membrane of the renal collecting duct cells [63]D[64]D.
This binding triggers a signaling cascade:
- Activation of Adenylate Cyclase: Increases intracellular cyclic adenosine monophosphate (cAMP) [64]D.
- AQP2 Translocation: cAMP-dependent protein kinase A phosphorylates aquaporin-2 (AQP2) water channels, promoting their translocation from intracellular vesicles to the apical (luminal) membrane [64]D.
- Water Reabsorption: The apical membrane becomes highly permeable to water, allowing free water to move along an osmotic gradient from the tubule into the hypertonic medullary interstitium and then into the systemic circulation [64]D[86]D.
The "Vasopressin Escape" and Euvolemia
Patients with SIADH typically present as euvolemic rather than hypervolemic [81]D. This is maintained through two primary mechanisms:
- Secondary Natriuresis: The initial mild volume expansion stimulates the release of atrial natriuretic peptide (ANP) and brain natriuretic peptide (BNP) [91]D. These peptides promote urinary sodium excretion (natriuresis) to restore volume, which further exacerbates hyponatremia [91]D.
- Vasopressin Escape: To prevent progressive volume expansion, the kidneys eventually downregulate AQP2 expression despite persistently high AVP levels, a phenomenon known as "vasopressin escape" [64]D.
Nephrogenic Syndrome of Inappropriate Antidiuresis (NSIAD)
SIADH must be distinguished from NSIAD, which presents with an identical clinical phenotype but suppressed plasma AVP levels [63]D. NSIAD is caused by gain-of-function mutations in the AVPR2 gene, leading to constitutive activation of the V2 receptor and continuous water reabsorption regardless of AVP presence [63]D[87]C.
Biomarkers: AVP and Copeptin
While AVP is the primary driver, it is unstable in plasma and difficult to measure [82]D. Copeptin, the C-terminal glycopeptide of the AVP precursor, is secreted in equimolar amounts to AVP [82]D[84]D. It is more stable and serves as a reliable surrogate biomarker for AVP activity in diagnosing osmoregulatory disorders [82]D[88]C[94]D.
Etiology and Triggers
SIADH arises from diverse pathologies that interfere with the osmoregulatory system or produce ectopic AVP. Recent evidence suggests that endogenous fructose production via the polyol pathway may also stimulate vasopressin secretion [97]D.
| Category | Specific Causes and Conditions |
|---|---|
| Malignancies | Small cell lung cancer (SCLC) [66]C, Ectopic or orthotopic olfactory neuroblastoma (ONB) [29][87]C, Large cell neuroendocrine carcinoma (LCNEC) of the cervix [96]C, Sellar neurocytoma [98]D, Suprasellar germ cell tumors [101]C. |
| CNS Disorders | Traumatic brain injury (TBI) [93]D, Tuberculous meningitis [91]D, Spinal cord injury [89]D, Suprasellar arachnoid cysts [88]C[100]C, Craniopharyngioma [92]D. |
| Post-Surgical | Transsphenoidal surgery for pituitary adenomas or Cushing disease [95]C[99]D, General neurosurgical procedures [85]D[88]C. |
| Infections | Brucellosis [39], Tuberculous meningitis [91]D. |
| Drug-Induced | Desmopressin (used for nocturnal polyuria), Oxytocin (used for labor induction) [63]D. |
| Other | Restrictive eating [87]C, Fructose ingestion [97]D, Decompensated cirrhosis (dilutional component) [90]D. |
Clinical Features
- ▸SIADH typically presents as euvolemic hyponatremia, lacking clinical signs of edema or dehydration.
- ▸Chronic 'asymptomatic' hyponatremia is strongly associated with a two- to three-fold increase in bone fractures and osteoporosis.
- ▸Severe neurological symptoms like seizures and coma are more common in acute declines of serum sodium below 120 mmol/L.
The clinical presentation of the (SIADH) is highly variable. It ranges from an asymptomatic state to life-threatening neurological emergencies [2]D[60]D. The severity of symptoms depends primarily on the absolute level of hyponatremia and the rapidity of the decline in serum sodium [2]D[10]D. Patients typically present as clinically euvolemic, lacking signs of fluid overload (e.g., edema) or volume depletion (e.g., dehydration) [11]C[108]C.
Acute and Severe Manifestations
Acute hyponatremia (developing in <48 hours) often leads to cerebral edema as water shifts into brain cells [11]C[111]C. Severe neurological symptoms typically manifest when serum sodium falls below 120-125 mmol/L [79][105]C[112]C.
- Early Symptoms: Nausea, malaise, and headache [108]C.
- Moderate Symptoms: Disorientation, confusion, agitation, and phasic troubles (aphasia) [12]C[108]C[112]C.
- Severe Symptoms: Stupor, generalized tonic-clonic seizures, and coma [108]C[111]C.
- Radiographic Findings: Brain computerized tomography (CT) may reveal diffuse cerebral edema in severe cases [11]C.
Chronic Hyponatremia and Bone Health
Chronic SIADH is often labeled 'asymptomatic,' but subtle deficits are common, particularly in elderly populations [106]C[109]D. Even mild hyponatremia is associated with significant morbidity [109]D.
- Neurocognitive Deficits: Progressive dementia, impaired level of consciousness, and abnormal behaviors such as hoarding, talkativeness, or delusions [18]C[23]C.
- Gait and Balance: Increased risk of gait instability and falls [109]D.
- Bone Health: Chronic hyponatremia is a significant independent risk factor for osteoporosis and a two- to three-fold increase in bone fractures [109]D. Pathophysiological mechanisms include increased bone resorption to mobilize sodium and increased fall frequency [109]D.
Atypical and Rare Presentations
SIADH can present with unusual clinical features that may delay diagnosis if not recognized as manifestations of hyponatremia [105]C.
- Persistent Hiccups: Severe hyponatremia (Na 122.4 mEq/L) has been reported to cause intractable hiccups that resolve only upon sodium correction [105]C.
- Takotsubo Syndrome: Also known as stress cardiomyopathy, this can be triggered by severe hyponatremia (Na 119 mmol/L), presenting with angina, elevated cardiac enzymes, and ST-segment elevation [19]C.
- Cerebellar Deficits: While rare, some patients present with acute ataxia and cerebellar symptomatology [11]C[24]C.
- Psychosis: Subacute psychosis and acute behavioral changes may be the primary manifestation in cases associated with [23]C.
Etiology-Specific Clinical Clues
The underlying cause of SIADH often contributes its own clinical signature to the presentation [60]D.
- Malignancy: Patients with (SCLC) or olfactory neuroblastoma may present with weight loss, cough, or paranasal sinus symptoms alongside SIADH [71]C[87]C. SCLC may also present with concomitant (LEMS), characterized by proximal muscle weakness [24]C.
- Infections: West Nile Virus or Varicella Zoster Virus (VZV) infections may present with fever, neck pain, and photophobia (meningism) [20]C[106]C.
- Neurological Disorders: Normal pressure hydrocephalus (NPH) may present with the classic triad of gait disturbance, urinary incontinence, and cognitive decline, exacerbated by SIADH-induced confusion [104]C.
- Drug-Induced: Symptoms may emerge shortly after initiating medications such as Vortioxetine, Pramipexole, or Osimertinib [6]C[103]C[108]C.
| Severity | Serum Sodium (mmol/L) | Common Clinical Features |
|---|---|---|
| Mild | 130 – 135 | Often asymptomatic; subtle cognitive impairment; gait instability [107]D[109]D |
| Moderate | 125 – 129 | Nausea, headache, confusion, malaise, disorientation [79][108]C |
| Severe | < 125 | Seizures, stupor, coma, respiratory arrest, cerebral edema [11]C[111]C[112]C |
| Manifestation | Clinical Description | Reference |
|---|---|---|
| Persistent Hiccups | Intractable hiccups resolving only with sodium normalization | [105]C |
| Takotsubo Syndrome | Reversible left ventricular dysfunction, angina, and ST-elevation | [19]C |
| Cerebellar Ataxia | Impaired coordination and gait mimicking cerebellar stroke | [11]C |
| Psychosis | Acute psychosis, delusions, and hoarding behaviors | [23]C |
| Phasic Troubles | Acute aphasia or speech difficulties | [12]C |
Diagnostic Criteria
- ▸SIADH is a diagnosis of exclusion requiring the presence of hypotonic hyponatremia, inappropriate urine concentration (>100 mOsm/kg), and clinical euvolemia.
- ▸Fractional excretion of uric acid (FEUrate) >12% is a critical supplemental marker to distinguish SIADH from diuretic-induced hyponatremia.
- ▸Normal adrenal and thyroid function must be biochemically confirmed to satisfy the essential diagnostic criteria.
The diagnosis of the Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH) is established through a combination of clinical assessment and biochemical markers [76]D[123]D. It is primarily a diagnosis of exclusion, requiring the presence of hypotonic hyponatremia in a clinically euvolemic patient without alternative causes for vasopressin release [123]D[130]C. The formal framework, often referred to as the Bartter and Schwartz criteria, categorizes findings into essential and supplemental criteria [123]D[130]C.
Essential Diagnostic Criteria
To confirm a diagnosis of SIADH, all of the following essential criteria must be met [123]D[125]D:
- Hypotonic Hyponatremia: Serum sodium <135 mEq/L and measured serum osmolality <275 mOsm/kg [91]D[123]D[127]D.
- Inappropriate Urine Concentration: Urine osmolality >100 mOsm/kg in the presence of serum hypotonicity [123]D[125]D.
- Clinical Euvolemia: Absence of clinical signs of volume depletion (e.g., orthostatic hypotension, tachycardia, dry mucous membranes) or volume excess (e.g., peripheral edema, ascites, jugular venous distension) [11]C[115]D[133]D.
- Elevated Urinary Sodium: Spot urinary sodium concentration (U-Na >30-40 mmol/L) while on a standard salt and water intake [113][123]D[125]D.
- Exclusion of Other Hypotonic States: Normal thyroid function (TSH) and normal adrenal function (cortisol) must be documented [123]D[124]D.
- Absence of Diuretics: The patient must not have recently used diuretic medications, particularly thiazides, which can mimic the biochemical profile of SIADH [120]C[125]D.
Supplemental and Advanced Markers
Supplemental criteria are used to increase diagnostic certainty, especially when clinical volume status is ambiguous or diuretic use is a confounding factor [125]D:
- Fractional Excretion of Uric Acid (FEUrate): A FEUrate >12% is highly suggestive of SIADH. This remains a reliable marker even in patients taking diuretics, where urinary sodium may be misleadingly elevated [125]D.
- Serum Uric Acid: Hypouricemia (typically <4 mg/dL) is frequently observed due to increased urate clearance in the proximal tubule [121]D.
- Urine Calcium/Creatinine Ratio (UCa/UCr): Patients with SIADH typically exhibit a high UCa/UCr ratio (mean 0.23 ± 0.096). In contrast, patients with salt depletion or thiazide-induced hyponatremia typically show low ratios (<0.08) [122]D.
- Plasma Copeptin: Inappropriately elevated copeptin (a stable surrogate for arginine vasopressin) relative to low serum osmolality supports the diagnosis [117]C.
- Blood Urea Nitrogen (BUN): Often low (<10 mg/dL) due to the dilutional effect and increased urea clearance [30].
- Failure to Correct with Isotonic Saline: Unlike hypovolemic hyponatremia, SIADH does not improve (and may worsen) with the administration of 0.9% normal saline [125]D.
Differential Diagnosis
Accurate diagnosis requires differentiation from other hyponatremic syndromes that share similar features [113][120]C.
Cerebral Salt Wasting Syndrome (CSWS)
CSWS is frequently confused with SIADH in neurosurgical or traumatic brain injury (TBI) patients [113][114]C. While both present with high urinary sodium, CSWS is characterized by clinical hypovolemia and a high 24-hour total urinary sodium excretion, whereas SIADH patients are euvolemic [113].
Nephrogenic Syndrome of Inappropriate Antidiuresis (NSIAD)
NSIAD is a rare X-linked genetic variant caused by gain-of-function mutations in the V2 receptor [115]D. It is biochemically identical to SIADH (hyponatremia, high urine osmolality, euvolemia) but is distinguished by undetectable or suppressed levels of circulating arginine vasopressin (AVP) [115]D.
Exercise-Associated Hyponatremia (EAH)
EAH occurs acutely during or after endurance events like marathons [126]D. It fulfills the essential criteria for SIADH, driven by non-osmotic AVP secretion (often triggered by IL-6 or heat stress) combined with excessive hypotonic fluid ingestion [126]D[127]D.
Primary Polydipsia/Water Intoxication
In cases of voluntary excessive water ingestion, patients present with hyponatremia but will have maximally dilute urine (Urine Osmolality <100 mOsm/kg), which excludes SIADH [128]C.
| Laboratory Parameter | Threshold for SIADH | Clinical Context |
|---|---|---|
| Serum Sodium | <135 mEq/L | Defines hyponatremia [91]D[127]D |
| Serum Osmolality | <275 mOsm/kg | Confirms hypotonic state [123]D |
| Urine Osmolality | >100 mOsm/kg | Indicates impaired water excretion [125]D |
| Urinary Sodium (Spot) | >30-40 mmol/L | Reflects natriuresis in euvolemia [123]D |
| FEUrate | >12% | High specificity for SIADH vs. diuretics [125]D |
| UCa/UCr Ratio | ~0.23 | High in SIADH; low in salt depletion [122]D |
| Serum Uric Acid | <4 mg/dL | Common supplemental finding [121]D |
| Morning Cortisol | >10 µg/dL | Used to exclude adrenal insufficiency [124]D |
Laboratory Workup and Imaging
- ▸Diagnosis requires hypotonic hyponatremia (serum osmolality <275 mOsm/kg) with inappropriately concentrated urine (>100 mOsm/kg).
- ▸Fractional excretion of urate (FEurate) >12% is a highly specific marker for SIADH, distinguishing it from hypovolemic states.
- ▸Copeptin serves as a stable, measurable surrogate for arginine vasopressin (AVP) and is elevated in SIADH despite low serum tonicity.
The diagnosis of the syndrome of inappropriate antidiuretic hormone secretion (SIADH) is a diagnosis of exclusion that requires the confirmation of hypotonic in a clinically euvolemic patient [137]D[139]C. Laboratory investigations must distinguish SIADH from other causes of hyponatremia, such as cerebral salt wasting (CSW), thiazide-induced hyponatremia, and adrenal insufficiency [48]D[145]D.
Essential Serum Investigations
Initial evaluation begins with a comprehensive metabolic panel and serum osmolality.
- Serum Sodium: Typically <135 mmol/L. Severe hyponatremia is defined as <120 mmol/L [91]D[150]C.
- Serum Osmolality: Must be <275 mOsm/kg to confirm hypotonicity [139]C[149]C.
- Blood Urea Nitrogen (BUN) and Creatinine: BUN is often low (<10 mg/dL) due to volume expansion and increased urea clearance [139]C[143]D.
- Serum Uric Acid: Hypouricemia (<4 mg/dL) is a classic finding in SIADH due to increased fractional excretion of urate [48]D[121]D.
- Potassium and Acid-Base Balance: Usually normal in SIADH, helping to exclude mineralocorticoid deficiency [144]C[149]C.
- Magnesium and Phosphate: In specific cases like anti-LGI1 encephalitis, concurrent hypomagnesemia and hypophosphatemia may be observed [138]D.
Urine Analysis and Fractional Excretions
Urinary markers are critical for assessing the appropriateness of antidiuretic hormone (ADH) activity relative to serum tonicity.
- Urine Osmolality: Inappropriately concentrated urine (>100 mOsm/kg) in the presence of serum hypo-osmolality is the hallmark of SIADH [139]C[149]C. Values often exceed 500 mOsm/kg in acute cases [8]C[88]C.
- Urine Sodium (UNa): Typically >30 mmol/L with normal salt intake [8]C[149]C. In severe SIADH, UNa can exceed 130 mmol/L [8]C.
- Fractional Excretion of Urate (FEurate): An FEurate >12% is highly suggestive of SIADH and helps differentiate it from volume depletion (where FEurate is low) [48]D[136].
- Urine Calcium/Creatinine Ratio: A high ratio (>0.20) is associated with SIADH, whereas salt depletion and thiazide use typically present with low ratios (<0.07) [122]D.
- Fractional Excretion of Phosphate (FEphosphate): Elevated FEphosphate may help distinguish SIADH from CSW in pediatric populations [136].
Advanced Biomarkers
While direct measurement of arginine vasopressin (AVP) is technically difficult due to its short half-life and instability, surrogate markers are increasingly utilized [82]D[141]D.
- Copeptin: Cleaved from the same precursor as AVP, copeptin is stable and released in equimolar amounts [82]D[84]D. In SIADH, copeptin levels are inappropriately elevated relative to low serum osmolality [117]C[146]C. Thresholds of >3.8 to 4.9 pmol/L have been suggested in post-traumatic settings [141]D.
- Natriuretic Peptides: Brain natriuretic peptide (BNP) or NT-proBNP levels are often higher in CSW than in SIADH, aiding in the differential diagnosis of neurogenic hyponatremia [136][140]D.
Imaging and Etiological Workup
Once SIADH is biochemically confirmed, imaging is required to identify the underlying trigger [142]C[149]C.
- Neuroimaging (CT/MRI): Indicated to detect central nervous system (CNS) causes such as , , hypothalamic hamartomas, or subarachnoid hemorrhage [28][140]D[146]C. MRI may show vasogenic edema in cases of posterior reversible encephalopathy syndrome (PRES) associated with autonomic dysfunction [148]C.
- Chest Imaging (Chest X-ray or CT): Essential to screen for pulmonary causes, particularly (SCLC), which is a frequent paraneoplastic source of ectopic ADH [66]C.
- Abdominal Imaging: May be necessary to exclude occult malignancies or conditions like hereditary tyrosinemia type 1, which presents with elevated urinary δ-aminolevulinic acid (ALA) [117]C.
| Parameter | SIADH | Cerebral Salt Wasting (CSW) |
|---|---|---|
| Volume Status | Euvolemic | Hypovolemic [136][140]D |
| Urine Sodium | Elevated (>30 mmol/L) | Markedly Elevated [8]C[140]D |
| Urine Volume | Normal or Decreased | Increased (Polyuria) [140]D |
| Serum Uric Acid | Low (<4 mg/dL) | Low to Normal [48]D[136] |
| BNP / NT-proBNP | Normal to Mildly Elevated | Significantly Elevated [136][140]D |
| FEurate | Elevated (>12%) | Elevated [48]D[136] |
| Response to Saline | Worsening Hyponatremia | Improvement in Sodium [8]C[147]C |
Differential Diagnosis
- ▸The fractional excretion of uric acid (FE Urate) is a critical tool: in SIADH, it normalizes (>12% to <10%) after sodium correction, whereas in CSW, it remains elevated.
- ▸Primary polydipsia is distinguished from SIADH by maximally dilute urine (Uosm <100 mOsm/kg) and suppressed copeptin levels.
- ▸Reset osmostat allows for normal urinary dilution once the patient reaches a lower-than-normal osmolality threshold, unlike the fixed concentration seen in classic SIADH.
The differential diagnosis of the (SIADH) involves distinguishing it from other causes of hypotonic hyponatremia. Because SIADH is a diagnosis of exclusion, clinicians must systematically rule out conditions that mimic its biochemical profile, particularly in neurosurgical and psychiatric settings [62]D, [137]D.
Volume Status Assessment
Accurate assessment of extracellular fluid (ECF) volume is the primary step in differentiation. SIADH is characterized by euvolemia, whereas other conditions present with hypovolemia or hypervolemia [161]D.
- Hypovolemic Hyponatremia: Includes gastrointestinal losses, diuretic use, and (CSWS) [151]C, [152]D.
- Hypervolemic Hyponatremia: Includes congestive heart failure, , and nephrotic syndrome [48]D, [122]D.
- Euvolemic Hyponatremia: Includes SIADH, , secondary adrenal insufficiency, and [48]D, [144]C.
SIADH vs. Cerebral Salt Wasting (CSW)
Differentiating SIADH from CSW is a major clinical challenge, especially following (TBI), subarachnoid hemorrhage, or pituitary surgery [153]D, [159]C, [160]D. While both present with hyponatremia and high urine sodium (UNa >30 mmol/L), their pathophysiology and volume status differ fundamentally [152]D, [156]D.
| Feature | SIADH | Cerebral Salt Wasting (CSW) |
|---|---|---|
| Volume Status | Euvolemic/Mildly Hypervolemic | Hypovolemic (Volume Depletion) [152]D |
| Pathophysiology | Primary water retention [62]D | Primary natriuresis (salt wasting) [48]D |
| Urine Output | Usually low or normal | Polyuria (high output) [151]C |
| Serum Urate | Low (<4 mg/dL) [48]D | Low (<4 mg/dL) [48]D |
| FE Urate | >12% (normalizes after Na correction) [17]C | >12% (remains elevated after Na correction) [48]D |
| Response to Fluids | Worsens hyponatremia [8]C | Improves hyponatremia [151]C |
Reset Osmostat
Reset osmostat is considered a subtype of SIADH (Type C) where the hypothalamic threshold for ADH release is set at a lower-than-normal plasma osmolality [152]D, [157]C. Unlike classic SIADH, patients with a reset osmostat can dilute their urine normally once their new, lower osmolality threshold is reached [162]C. This condition is often associated with chronic illness, pregnancy, or hypothalamic injury, such as from a giant arachnoid cyst [157]C.
Thiazide-Associated Hyponatremia (TAH)
Thiazide diuretics can produce a biochemical picture nearly identical to SIADH, including low serum osmolality and high urine osmolality [145]D. Differentiation relies on the clinical history of drug use. The urine chloride and potassium score (ChU) and fractional excretion of uric acid (FEUA) are helpful; TAH typically presents with lower urine calcium levels compared to SIADH [122]D, [145]D.
Primary Polydipsia and Water Intoxication
Psychiatric patients often present with severe hyponatremia due to excessive water intake [154]. In primary polydipsia, the ADH suppression mechanism is intact, resulting in maximally dilute urine (Urine Osmolality <100 mOsm/kg) [161]D. This contrasts with SIADH, where urine is inappropriately concentrated (Urine Osmolality >100 mOsm/kg, often >300 mOsm/kg) [8]C, [67]C. Measurement of can assist in this distinction, as levels are suppressed in primary polydipsia but elevated or inappropriately "normal" in SIADH [82]D, [158]D.
Endocrine and Systemic Mimics
Several systemic conditions must be excluded before confirming SIADH:
- Adrenal Insufficiency: Mineralocorticoid deficiency (Addison's disease) causes salt wasting and must be ruled out via cortisol testing [48]D, [144]C.
- Hypothyroidism: Severe hypothyroidism can impair free water excretion [144]C.
- Guillain-Barré Syndrome (GBS): Hyponatremia in GBS may be due to SIADH or autonomic dysfunction [155]D.
- Spinal Cord Injury: Acute injury can lead to complex dysregulation of AVP and sodium [89]D.
- Hashimoto Encephalopathy: Rare cases present with psychosis and SIADH-like biochemistry [23]C.
- Malignancy: Small cell carcinoma (lung or cervix) can ectopically secrete ADH [112]C.
| Condition | Serum Osmolality | Urine Osmolality | Urine Sodium (UNa) | FE Urate |
|---|---|---|---|---|
| SIADH | Low | >100 mOsm/kg | >30 mmol/L | >12% |
| CSW | Low | >100 mOsm/kg | >40 mmol/L | >12% (Persistent) |
| Primary Polydipsia | Low | <100 mOsm/kg | Variable | <10% |
| Hypovolemia (GI loss) | Low | >100 mOsm/kg | <20 mmol/L | <10% |
| Thiazide Use | Low | >100 mOsm/kg | >30 mmol/L | Variable |
Management
- ▸Acute symptomatic hyponatremia requires rapid correction with 3% hypertonic saline boluses (100–150 mL) to prevent cerebral edema.
- ▸Fluid restriction (<1000 mL/day) is the first-line treatment for chronic SIADH but has a failure rate of approximately 50%.
- ▸Low-dose tolvaptan (7.5 mg) is an effective alternative to standard 15 mg dosing, providing sodium correction with a reduced risk of osmotic demyelination syndrome.
The management of the (SIADH) is determined by the severity of neurological symptoms, the duration of , and the underlying etiology [2]D[60]D. The primary therapeutic goals are to prevent life-threatening cerebral edema in acute cases and to achieve a controlled, gradual increase in serum sodium (sNa) in chronic cases to avoid (ODS) [2]D[163].
Acute Management of Symptomatic Hyponatremia
For patients presenting with severe symptoms (e.g., seizures, coma, or respiratory failure), urgent intervention is required regardless of the underlying cause [2]D[107]D.
- Hypertonic Saline (3% NaCl): Administer a 100–150 mL intravenous bolus over 10–20 minutes [107]D. This may be repeated up to three times or until symptoms improve [107]D.
- Correction Targets: The goal is a rapid increase of 4–6 mmol/L in sNa within the first 24 hours [2]D. Total correction should not exceed 10 mmol/L in 24 hours or 18 mmol/L in 48 hours to minimize ODS risk [2]D[164].
- Monitoring: Biochemical monitoring of sNa and volume status should occur every 1–4 hours during the acute phase [107]D.
First-Line Chronic Management
In asymptomatic or mildly symptomatic patients, conservative measures are preferred [107]D.
- Fluid Restriction (FR): This remains the conventional first-line therapy [79][107]D. Typical restriction levels are <800–1000 mL/day [79][87]C. However, FR is often unsuccessful in up to 50% of patients, particularly those with high urinary osmolality or low solute intake [107]D.
- Treatment of Underlying Cause: Removal of the stimulus for inappropriate vasopressin secretion is the most effective long-term therapy [60]D. This includes discontinuing offending medications (e.g., , ) [170]C, treating infections (e.g., Klebsiella pneumoniae) [166]C, or initiating chemotherapy/radiotherapy for paraneoplastic SIADH (e.g., ) [57]C[66]C[71]C[96]C.
Pharmacological Interventions
When fluid restriction is insufficient or poorly tolerated, pharmacological agents are indicated [79][80].
Vasopressin Receptor Antagonists (Vaptans)
Tolvaptan is a selective V2-receptor antagonist that promotes aquaresis (electrolyte-free water excretion) [79][163].
- Dosing: While the standard licensed dose is 15 mg daily, recent evidence supports starting at 7.5 mg daily or even 3.75 mg daily to reduce the risk of overcorrection [163][164][165][167].
- Efficacy: Tolvaptan is significantly more effective than fluid restriction at normalizing sodium levels (Na ≥135 mmol/L) [79][167].
- Safety: If sNa correction exceeds safe limits, intervention with 5% dextrose or may be required [79].
Oral Urea
Urea induces osmotic diuresis, increasing free water clearance [30][169]D.
- Dosing: Typically administered as 15–30 g daily (or 0.25–0.5 g/kg) [30][169]D.
- Clinical Utility: It is particularly useful in oncology settings for chronic SIADH management [169]D. It is generally well-tolerated, though palatability can be an issue [30].
Emerging and Alternative Therapies
- SGLT2 Inhibitors: Agents like (10 mg daily) are emerging as a novel strategy by promoting osmotic diuresis via glucosuria [81]D.
- Loop Diuretics and Salt Tablets: Oral sodium chloride (1–3 g TID) combined with low-dose loop diuretics (e.g., 20–40 mg daily) can be used to increase solute load and water excretion [60]D[80].
- Demeclocycline: Historically used to induce a form of nephrogenic , its use has declined due to nephrotoxicity and the availability of vaptans [81]D.
- UT-A1 Inhibitors: Experimental urea transporter inhibitors are under investigation as future diuretics that do not cause electrolyte loss [143]D.
| Medication | Mechanism | Typical Dosage | Clinical Considerations |
|---|---|---|---|
| Tolvaptan | V2-receptor antagonist | 7.5–15 mg PO daily | High risk of overcorrection; monitor sNa closely [79][164] |
| Urea | Osmotic diuretic | 15–30 g PO daily | Effective in oncology; limited by palatability [30][169]D |
| Hypertonic Saline (3%) | Direct sodium replacement | 100–150 mL IV bolus | Reserved for severe neurological symptoms [107]D |
| Empagliflozin | SGLT2 inhibitor | 10 mg PO daily | Emerging therapy; promotes osmotic diuresis [81]D |
| Furosemide | Loop diuretic | 20–40 mg PO daily | Often combined with salt tablets (1–3 g TID) [60]D[80] |
Complications and Prognosis
- ▸Chronic SIADH is a major cause of 'silent' morbidity, including gait instability, falls, and osteoporosis-related fractures.
- ▸The most severe treatment complication is Osmotic Demyelination Syndrome (ODS), occurring when sodium correction exceeds 10–12 mmol/L in 24 hours.
- ▸Hyponatremia is an independent predictor of mortality in diverse conditions such as lung cancer, stroke, and COVID-19.
The complications of the syndrome of inappropriate antidiuretic hormone secretion (SIADH) arise from two distinct mechanisms: the physiological effects of hypotonicity on organ systems and the neurological risks associated with rapid therapeutic correction [5]D[177]D. Even mild, chronic hyponatremia is associated with significant morbidity and serves as an independent predictor of mortality across various clinical settings [181]D.
Chronic Morbidity and Systemic Effects
Chronic SIADH is no longer considered an asymptomatic condition. Persistent hyponatremia leads to subtle but impactful systemic impairments [181]D.
- Neurological and Functional Decline: Patients often exhibit cognitive impairment, attention deficits, and dizziness [181]D. Gait instability is a hallmark of chronic SIADH, significantly increasing the risk of falls [5]D[177]D.
- Bone and Muscular Health: Hyponatremia directly affects bone metabolism, leading to and an increased incidence of bone fractures [177]D[181]D. This is compounded by sarcopenia (muscle wasting) and hypercalciuria, which may also predispose patients to kidney stones [181]D.
- Cellular Effects: In vitro data suggest that low extracellular sodium concentrations may increase cellular proliferation and motility [181]D.
Acute and Severe Complications
When serum sodium levels drop rapidly or reach profound levels (typically <120 mmol/L), the risk of life-threatening complications increases [5]D[176]C.
- Neurological Emergencies: Severe hyponatremia can manifest as cerebral edema, leading to seizures, coma, and respiratory arrest [5]D[154].
- Cardiovascular Impact: Although rare, severe acute hyponatremia (<120 mmol/L) has been identified as a precipitant for (stress-induced cardiomyopathy), characterized by reversible left ventricular apical ballooning [176]C.
Treatment-Related Complications
The primary risk during the management of SIADH is the rapid overcorrection of serum sodium, particularly in chronic cases where the brain has undergone osmotic adaptation [2]D[10]D.
- Osmotic Demyelination Syndrome (ODS): Rapid correction causes water to move out of brain cells, leading to cellular dehydration and demyelination, particularly in the pons [2]D[173]. ODS can result in permanent neurological deficits or death [10]D.
- Overcorrection Thresholds: Risks are highest when sodium correction exceeds 10–12 mmol/L within 24 hours or 18 mmol/L within 48 hours [2]D[164]. Studies on low-dose (7.5 mg) show that even at reduced doses, approximately 8.7% of patients may still exceed correction limits of ≥10 mmol/L within the first 24 hours [164].
Prognostic Significance by Underlying Condition
Hyponatremia in the context of SIADH is a negative prognostic indicator for several primary diseases, often correlating with increased hospital length of stay (LOS) and higher mortality rates [37][107]D[180]D.
| Condition | Prognostic Impact of SIADH/Hyponatremia | Reference |
|---|---|---|
| Lung Cancer | Average prevalence of 26.4%; significantly worsens survival outcomes. | [33][58] |
| Acute Stroke | Most common electrolyte imbalance; linked to higher mortality and poor functional recovery. | [37] |
| COVID-19 | Associated with increased mortality and longer hospital stays; euvolemic SIADH is the most common type. | [38][180]D |
| Guillain-Barré Syndrome | Linked to more severe in-hospital course, higher costs, and worse functional status at 1 year. | [41]D[155]D |
| Severe Hyponatremia | Overall mortality rates range from 4% to 40%. | [154] |
| Neurocritical Care | Negative prognostic factor in traumatic brain injury (TBI) and subarachnoid hemorrhage. | [175] |
In patients with (SCLC), the presence of SIADH is a well-documented marker of poor prognosis, though successful correction of sodium levels may improve survival in some cohorts [58]. In neurosurgical and neurocritical care populations, SIADH-induced hyponatremia complicates the management of cerebral edema and is associated with worse neurological outcomes [85]D[175].
| System | Complication | Mechanism |
|---|---|---|
| Neurological | Cognitive decline, gait instability | Osmotic shifts and metabolic encephalopathy [181]D |
| Musculoskeletal | Osteoporosis, sarcopenia, fractures | Direct bone resorption and increased fall risk [177]D[181]D |
| Renal | Hypercalciuria, nephrolithiasis | Altered calcium handling in SIADH [181]D |
| Psychiatric | Increased risk in polydipsia/antipsychotic use | Drug-induced ADH secretion or water intake [154] |
Special Populations
- ▸Postoperative SIADH is a leading cause of hospital readmission after transsphenoidal surgery, often occurring as part of a triphasic fluid balance response.
- ▸The use of hypotonic intravenous fluids in children with acute infections significantly elevates the risk of severe hyponatremia (<130 mmol/L).
- ▸Copeptin serves as a critical surrogate biomarker for AVP in pediatric and neurosurgical populations to differentiate SIADH from diabetes insipidus.
The clinical presentation and management of SIADH vary significantly across specific patient cohorts, particularly in neurosurgical, pediatric, and oncological settings. These populations often exhibit unique triggers, such as surgical manipulation of the hypothalamic-pituitary axis, acute childhood infections, or rare paraneoplastic syndromes.
Postoperative Neurosurgical Patients
Hyponatremia is the most frequent electrolyte disturbance following pituitary surgery, with an incidence ranging from 9% to 30.7% [34], [182]D. In a large cohort of 670 patients, the incidence was reported at 24.2%, with a mean nadir sodium of 128.6 mmol/L [99]D. Risk factors for postoperative SIADH include female gender and younger age [99]D.
Surgical procedures associated with SIADH include (TSS) for [28], [192]D, transcranial resection of tuberculum sellae meningiomas [32], and endoscopic resection of craniopharyngiomas [191]D. In craniopharyngioma cases, the development of SIADH is often part of a triphasic response: an initial phase of (DI), followed by a period of SIADH, and potentially a permanent return to DI [191]D, [88]C.
Diagnosis in this setting requires differentiation from (CSWS). Diagnostic markers include plasma brain natriuretic peptide (BNP), 24-hour urine sodium, and the diameter of the inferior vena cava (IVCD) [140]D. Elevated urinary oxytocin (OXT) levels between postoperative days 1 and 4 have also been correlated with increased natriuresis and the development of hyponatremia [189]D. Novel monitoring strategies include the use of smartphone applications for remote symptom tracking [184]D.
Pediatric Population
SIADH is a common cause of euvolemic hyponatremia in hospitalized children [188]D. Pediatric cases are frequently triggered by non-physiologic stimuli for vasopressin production during acute illnesses such as bronchiolitis, acute gastroenteritis, encephalitis, and meningitis [186]D. The risk of severe hyponatremia (<130 mmol/L) is significantly increased by the administration of hypotonic intravenous fluids [186]D.
Diagnostic advancements in pediatrics include the measurement of copeptin, a surrogate biomarker for arginine vasopressin (AVP) [84]D. Copeptin levels help distinguish SIADH from DI and are particularly useful in managing complex postsurgical osmoregulatory disorders in infants [88]C.
Oncology and Rare Associations
Paraneoplastic SIADH is well-documented in various malignancies. Rare causes include ectopic olfactory neuroblastoma, where sodium levels may correct within 24 hours of endoscopic resection [68]C. In such cases, may be utilized to prevent overly rapid sodium correction and subsequent neurologic sequelae [68]C.
Medication-induced SIADH in special populations includes:
- Osimertinib: A third-generation EGFR-TKI used in lung adenocarcinoma; SIADH may resolve with dose reduction [6]C.
- Duloxetine: Reported to cause SIADH in pediatric oncology patients treated for chemotherapy-induced neuropathic pain [183]C.
Additionally, SIADH has been rarely associated with (ALS), potentially exacerbated by postoperative stress following unrelated procedures like hip replacement [142]C.
Exercise-Associated Hyponatremia (EAH)
In endurance athletes, such as marathon runners, SIADH-like physiology may contribute to exercise-associated hyponatremia. Recent research suggests that fructose ingestion or endogenous fructose production via the polyol pathway may stimulate vasopressin secretion, providing a potential mechanism for EAH [97]D.
| Category | Specific Causes/Triggers | Reference |
|---|---|---|
| Neurosurgical | Transsphenoidal surgery, Tuberculum sellae meningioma resection, Craniopharyngioma resection, Hypothalamic tumor surgery, Arachnoid cyst fenestration | [32], [140]D, [187]D, [191]D, [192]D |
| Pediatric Infections | Bronchiolitis, Acute gastroenteritis, Encephalitis, Meningitis | [186]D |
| Pharmacological | Osimertinib, Duloxetine | [6]C, [183]C |
| Neurological | Amyotrophic lateral sclerosis (ALS), Subarachnoid hemorrhage | [46]D, [142]C |
| Oncological | Ectopic olfactory neuroblastoma, Lung adenocarcinoma | [6]C, [68]C |
| Lifestyle/Other | Long-distance running (Exercise-associated), Fructose ingestion | [97]D |
| Intervention | Population/Context | Details | Reference |
|---|---|---|---|
| Fluid Restriction | Post-pituitary surgery | 1000 mL/day for 7 days | [34], [192]D |
| Tolvaptan | Post-transsphenoidal surgery | Used for acute euvolemic hyponatremia | [193]D |
| Dietary DI Bundle | Pituitary region tumors | Avoid added salt, high-protein foods, and caffeine | [83] |
| Desmopressin | Post-resection of neuroblastoma | Used to prevent rapid sodium overcorrection | [68]C |
| Dose Reduction | Osimertinib-induced SIADH | Allows continuation of therapy | [6]C |
| Standard Pediatric | Hospitalized children | Oral urea, loop diuretics, oral sodium supplements | [188]D |
Guidelines and Resources
- ▸The European guidelines (2014) prioritize the severity of clinical symptoms (e.g., seizures, coma) over absolute sodium levels for determining treatment urgency.
- ▸A 48-hour threshold is used to distinguish between acute and chronic hyponatremia, which significantly influences the risk of osmotic demyelination.
- ▸European guidelines recommend against the use of vaptans in hospitalized patients with moderate to profound hyponatremia due to overcorrection risks.
Clinical management of the (SIADH) is guided by several international and specialty-specific consensus statements. These guidelines focus on the classification of Hyponatremia , the rate of sodium correction to prevent (ODS), and the management of specific subsets like exercise-associated hyponatremia (EAH) and post-neurosurgical SIADH.
European Clinical Practice Guidelines (2014)
A joint task force representing the European Society of Intensive Care Medicine (ESICM), the European Society of Endocrinology (ESE), and the European Renal Association – European Dialysis and Transplant Association (ERA-EDTA) published comprehensive guidelines in 2014 [194][195]. These guidelines define hyponatremia as a serum sodium concentration <135 mmol/L [194].
The European guidelines prioritize the severity of clinical symptoms over the absolute biochemical level of sodium when determining the urgency of treatment. They distinguish between "moderately severe" and "severe" symptoms to guide intervention [194].
Symptom Classification [194]:
- Severe Symptoms: Vomiting, cardiorespiratory distress, abnormal and deep somnolence, seizures, and coma (Glasgow Coma Scale ≤8).
- Moderately Severe Symptoms: Nausea (without vomiting), confusion, and headache.
For chronicity, the guidelines use a 48-hour threshold. Hyponatremia is considered "acute" if it has lasted <48 hours and "chronic" if it has lasted ≥48 hours or if the duration is unknown [194]. A critical recommendation from this panel is the avoidance of (vaptans) in hospitalized patients with moderate or profound hyponatremia, citing a lack of evidence for improved patient outcomes and concerns regarding overcorrection [194][195].
Spanish Consensus Algorithms (2013)
A multidisciplinary group of endocrinologists, nephrologists, internists, and pharmacists developed consensus algorithms for SIADH management in hospitalized patients [197]. These algorithms emphasize a tiered approach:
- First-line: Fluid restriction (typically 500–1000 mL/day) [197].
- Second-line: Pharmacological intervention with Urea (15–30 g/day) or Tolvaptan 15 mg/day (titrated up to 60 mg/day if needed) [197].
- Emergency: Hypertonic saline (3% NaCl) for symptomatic cases [197].
Wilderness Medical Society (WMS) Guidelines (2013-2014)
The WMS provides specific guidance for Exercise-Associated Hyponatremia (EAH), defined as a sodium concentration <135 mmol/L occurring during or up to 24 hours after prolonged physical activity [196][198]. These guidelines are tailored for austere environments where medical resources are limited. For symptomatic EAH, the WMS recommends an intravenous bolus of 100 mL of 3% NaCl, which may be repeated up to three times at 10–60 minute intervals if clinical improvement is not observed [196]. In less severe cases, oral hypertonic solutions (e.g., concentrated bouillon or salty snacks) are recommended [196].
Post-Pituitary Surgery Guidelines (2014)
Specific guidelines for managing water metabolism disorders after pituitary surgery emphasize the risk of a "triple phase" response (transient , followed by SIADH, then permanent diabetes insipidus) [199]. Recommendations include:
- Monitoring serum sodium every 24 hours for at least the first 5 days post-surgery [199].
- Careful differential diagnosis to distinguish SIADH from cerebral salt wasting (CSW) [199].
- Fluid restriction as the primary management for post-operative SIADH [199].
Sodium Correction Limits
All major guidelines emphasize strict limits on the rate of sodium elevation to mitigate the risk of ODS [194][197]. The European guidelines recommend a maximum increase of 10 mmol/L during the first 24 hours, followed by a limit of 8 mmol/L in every subsequent 24-hour period until a concentration of 130 mmol/L is reached [194].
| Classification | Serum Sodium Level | Clinical Context |
|---|---|---|
| Mild | 130–135 mmol/L | Often asymptomatic or subtle symptoms |
| Moderate | 125–129 mmol/L | May present with headache or confusion |
| Profound | <125 mmol/L | High risk for severe neurological symptoms |
| Acute | Duration <48 hours | Higher risk of cerebral edema |
| Chronic | Duration ≥48 hours | Higher risk of ODS during correction |
| Time Period | Maximum Sodium Increase | Source |
|---|---|---|
| First 24 Hours | 10 mmol/L | European Guidelines [194] |
| Subsequent 24 Hours | 8 mmol/L | European Guidelines [194] |
| Total in 48 Hours | 18 mmol/L | European Guidelines [194] |
| Target Level | 130 mmol/L | Stop active correction at this threshold [194] |
References
- [1]
Abufaraj M, Ramadan R, Alkhatib A. “Paraneoplastic Syndromes in Neuroendocrine Prostate Cancer: A Systematic Review.” Current oncology (Toronto, Ont.) (2024). PMID: 38534956 ↗
L2aSR_OBSCited in: Definition and Components - [2]
Alindogan A, Joseph R. “Disorders of Sodium.” Endocrinology and metabolism clinics of North America (2026). PMID: 41656034 ↗
L5REVIEW_NARRATIVECited in: Definition and Components, Clinical Features, Management, Complications and Prognosis - [3]
Dellal FD, Karaahmetli G, Guven SC et al.. “Eosinophilic granulomatosis with polyangiitis as a rare cause of the syndrome of inappropriate antidiuretic hormone secretion.” Irish journal of medical science (2023). PMID: 35895178 ↗
L4CASE_REPORTCited in: Definition and Components, Laboratory Workup and Imaging - [4]
Lindner G, Schwarz C, Haidinger M et al.. “Hyponatremia in the emergency department.” The American journal of emergency medicine (2022). PMID: 35870366 ↗
L5REVIEW_NARRATIVECited in: Definition and Components - [5]
Adrogué HJ, Tucker BM, Madias NE. “Diagnosis and Management of Hyponatremia: A Review.” JAMA (2022). PMID: 35852524 ↗
L5REVIEW_NARRATIVECited in: Definition and Components, Complications and Prognosis - [6]
Nishii M, Shimomura M, Okada S et al.. “Syndrome of inappropriate secretion of antidiuretic hormone (SIADH) by osimertinib and continued treatment with dose reduction for postoperative recurrence of lung adenocarcinoma: a case report.” Translational lung cancer research (2025). PMID: 41132965 ↗
L4CASE_REPORTCited in: Definition and Components, Etiology, Clinical Features, Special Populations - [7]
Arecco A, Demontis D, Della Sala L et al.. “Case report: Twice-daily tolvaptan dosing regimen in a challenging case of hyponatremia due to SIAD.” Frontiers in endocrinology (2023). PMID: 38288467 ↗
L4CASE_REPORTCited in: Definition and Components, Management - [8]
Lee LMY, Tan SYT, Loh WJ. “High Urinary Sodium Concentrations in Severe SIADH: Case Reports of 2 Patients and Literature Review.” Frontiers in medicine (2022). PMID: 35602488 ↗
L4CASE_REPORTCited in: Definition and Components, Laboratory Workup and Imaging, Differential Diagnosis - [9]
van Bockxmeer JJ, Lau A, Varshney V. “Ketamine-precipitated syndrome of inappropriate antidiuretic hormone secretion in a patient with persistent lumbar pain: a case report.” Canadian journal of anaesthesia = Journal canadien d'anesthesie (2022). PMID: 35233721 ↗
L4CASE_REPORTCited in: Definition and Components - [10]
Alindogan A, Joseph R. “Disorders of Sodium.” Emergency medicine clinics of North America (2023). PMID: 37758418 ↗
L5REVIEW_NARRATIVECited in: Definition and Components, Clinical Features, Complications and Prognosis - [11]
Tseriotis VS, Mitkani C, Lioliou F et al.. “Encephalopathy with cerebellar deficits in a context of hyponatremia.” Acta neurologica Belgica (2024). PMID: 39343832 ↗
L4CASE_REPORTCited in: Definition and Components, Clinical Features, Diagnostic Criteria - [12]
Thuerlimann AC, Morel J, Martin PY et al.. “Successful Treatment of SIADH after Removal of Ruptured Breast Implants.” Plastic and reconstructive surgery. Global open (2024). PMID: 38379779 ↗
L4CASE_REPORTCited in: Definition and Components, Etiology, Clinical Features - [13]
Villalvazo P, Fernandez-Prado R, Niño MDS et al.. “Who killed Bruce Lee? The hyponatraemia hypothesis.” Clinical kidney journal (2022). PMID: 36381374 ↗
L5OTHERCited in: Definition and Components, Epidemiology and Risk Factors, Etiology - [14]
Quigley N, Garneau AP, Haydock L et al.. “Extreme Hyponatremia Complicated by Osmotic Demyelination in a Previously Healthy Young Individual.” Canadian journal of kidney health and disease (2022). PMID: 36406868 ↗
L4CASE_REPORTCited in: Definition and Components - [15]
Wang AY, Wong TT, Hsieh KL et al.. “Giant cystic hypothalamic hamartoma in an infant associated with persistent syndrome of inappropriate antidiuretic hormone secretion.” Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery (2022). PMID: 35048169 ↗
L4CASE_REPORTCited in: Definition and Components - [16]
Zhou XH, Li Y, Wang CJ et al.. “[Syndrome of inappropriate antidiuretic hormone secretion after hematopoietic stem cell transplantation in a child: a case report and literature review].” Zhongguo dang dai er ke za zhi = Chinese journal of contemporary pediatrics (2026). PMID: 41766157 ↗
L4CASE_REPORTCited in: Definition and Components - [17]
Izquierdo Alarcón B, Castillo Pérez C, Jurado Parras P et al.. “Approach to hyponatremia: the value of fractional excretion of uric acid and phosphate.” Laboratory medicine (2026). PMID: 41886512 ↗
L4CASE_REPORTCited in: Definition and Components, Differential Diagnosis - [18]
Sato S, Arahata M, Kumano Y et al.. “Multiple endocrine neoplasia with an atypical clinical course and a MEN1 gene variant of uncertain pathogenicity: A case report.” Medicine (2026). PMID: 41760078 ↗
L4CASE_REPORTCited in: Definition and Components, Clinical Features, Diagnostic Criteria - [19]
López-Trejo FI, Cedillo-Urbina MR, Maldonado-Tenesaca AP et al.. “Hyponatraemia-induced Takotsubo syndrome secondary to idiopathic syndrome of inappropriate antidiuretic hormone: a case report.” European heart journal. Case reports (2025). PMID: 39925775 ↗
L4CASE_REPORTCited in: Definition and Components, Clinical Features - [20]
Tse JD, Wang J. “Neuroinflammation-Induced SIADH in West Nile Virus Infection: An Uncommon Neurological and Endocrine Manifestation.” The American journal of case reports (2024). PMID: 39340143 ↗
L4CASE_REPORTCited in: Definition and Components, Clinical Features - [21]
Thomas A, Finlay J, Sharp C. “Suspected paraneoplastic syndrome of inappropriate antidiuretic hormone secretion associated with a gastric adenocarcinoma in a dog.” Australian veterinary journal (2024). PMID: 39157893 ↗
L4CASE_REPORTCited in: Definition and Components - [22]
Gomaa A, Skelly R. “Pituitary macroadenoma apoplexy as a rare complication of Bruton tyrosine kinase inhibitor in chronic lymphoid leukaemia.” Chinese neurosurgical journal (2023). PMID: 37875968 ↗
L5OTHERCited in: Definition and Components - [23]
Okitsu M, Sugaya K, Yoneda M et al.. “Hashimoto Encephalopathy Presenting with Acute Psychosis and Inappropriate Secretion of Antidiuretic Hormone: A Rare Case Responding to Steroid Therapy.” The American journal of case reports (2023). PMID: 38085696 ↗
L4CASE_REPORTCited in: Definition and Components, Clinical Features, Differential Diagnosis - [24]
Oda Y, Tsubouchi H, Ishii N et al.. “A rare case of concomitant Lambert-Eaton myasthenic syndrome and syndrome of inappropriate antidiuretic hormone secretion in a patient with small cell lung carcinoma.” Respiratory medicine case reports (2023). PMID: 37920363 ↗
L4CASE_REPORTCited in: Definition and Components, Clinical Features - [25]
Marilda M, Rosa L, Stefano T et al.. “Syndrome of Inappropriate Antidiuresis and Diabetes Insipidus as Two Sides of the Same Coin in Hypothalamic Lymphoma: A Case Report.” Endocrine, metabolic & immune disorders drug targets (2023). PMID: 36424791 ↗
L4CASE_REPORTCited in: Definition and Components - [26]
Wang M, Zhang L, Jia M et al.. “Syndrome of inappropriate antidiuretic hormone secretion is associated with different proton pump inhibitor use: a pharmacovigilance study.” BMC nephrology (2022). PMID: 35590283 ↗
L5OTHERCited in: Definition and Components - [27]
Koizumi T, Kobayashi T, Kanda S et al.. “Syndrome of Inappropriate Antidiuretic Hormone Secretion as the Initial Presentation in a Patient with Stage I Small-cell Lung Cancer.” Internal medicine (Tokyo, Japan) (2022). PMID: 35228477 ↗
L4CASE_REPORTCited in: Definition and Components - [28]
Webb KL, Reilly CE, Hinkle ML et al.. “Incidence and risk factors of hyponatremia after transsphenoidal surgery: a systematic meta-analysis.” Neurosurgical review (2025). PMID: 40892282 ↗
L2aSR_OBSCited in: Epidemiology and Risk Factors, Laboratory Workup and Imaging, Management, Special Populations - [29]
Daloiso A, Gaudioso P, Vinciguerra A et al.. “Ectopic olfactory neuroblastoma is associated with increased frequency of syndrome of inappropriate antidiuretic hormone secretion and reduced disease control: Case series with systematic review and pooled analysis.” International forum of allergy & rhinology (2025). PMID: 39661032 ↗
L2aSR_OBSCited in: Epidemiology and Risk Factors, Pathophysiology - [30]
Chander S, Kumari R, Lohana AC et al.. “Urea to Treat Hyponatremia Due to Syndrome of Inappropriate Antidiuretic Hormone Secretion: A Systematic Review and Meta-Analysis.” American journal of kidney diseases : the official journal of the National Kidney Foundation (2025). PMID: 39362395 ↗
L2aSR_OBSCited in: Epidemiology and Risk Factors, Diagnostic Criteria, Management - [31]
Krisanapan P, Tangpanithandee S, Thongprayoon C et al.. “Safety and Efficacy of Vaptans in the Treatment of Hyponatremia from Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH): A Systematic Review and Meta-Analysis.” Journal of clinical medicine (2023). PMID: 37685548 ↗
L2aSR_OBSCited in: Epidemiology and Risk Factors, Pathophysiology, Complications and Prognosis - [32]
Martinez-Perez R, Kortz MW, Florez-Perdomo W et al.. “Endocrinological outcomes after transcranial resection of tuberculum sellae meningiomas: a systematic review and meta-analysis.” Neurosurgical review (2022). PMID: 35149901 ↗
L2aSR_OBSCited in: Epidemiology and Risk Factors, Special Populations - [33]
Bartalis E, Gergics M, Tinusz B et al.. “Prevalence and Prognostic Significance of Hyponatremia in Patients With Lung Cancer: Systematic Review and Meta-Analysis.” Frontiers in medicine (2021). PMID: 34950676 ↗
L2aSR_OBSCited in: Epidemiology and Risk Factors, Etiology, Complications and Prognosis - [34]
Perez-Vega C, Tripathi S, Domingo RA et al.. “Fluid Restriction After Transsphenoidal Surgery for the Prevention of Delayed Hyponatremia: A Systematic Review and Meta-Analysis.” Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists (2021). PMID: 34265453 ↗
L2aSR_OBSCited in: Epidemiology and Risk Factors, Special Populations - [35]
Skribek M, Bozoky B, Tsakonas G. “Osimertinib-induced syndrome of inappropriate secretion of antidiuretic hormone in oncogene-addicted lung adenocarcinoma: A case report.” Lung cancer (Amsterdam, Netherlands) (2022). PMID: 35276629 ↗
L4CASE_REPORTCited in: Epidemiology and Risk Factors, Etiology - [36]
Wardhana DPW, Soetomo CT, Satyarsa ABS et al.. “Critical shift phase in deep vein thrombosis development after major sellar region tumor surgeries: a systematic review.” Annals of medicine (2025). PMID: 41392925 ↗
L2aSR_OBSCited in: Epidemiology and Risk Factors, Special Populations - [37]
Hossain MF, Kharel M, Husna AU et al.. “Prevalence of Electrolyte Imbalance in Patients With Acute Stroke: A Systematic Review.” Cureus (2023). PMID: 37692728 ↗
L2aSR_OBSCited in: Epidemiology and Risk Factors, Complications and Prognosis - [38]
Khidir RJY, Ibrahim BAY, Adam MHM et al.. “Prevalence and outcomes of hyponatremia among COVID-19 patients: A systematic review and meta-analysis.” International journal of health sciences (2022). PMID: 36101848 ↗
L2aSR_OBSCited in: Epidemiology and Risk Factors, Complications and Prognosis - [39]
Mohamed MFH, Ahmed AOE, Habib MB et al.. “The prevalence of the syndrome of inappropriate antidiuretic hormone secretion (SIADH) in brucellosis patients: Systematic review and meta-analysis.” Annals of medicine and surgery (2012) (2022). PMID: 35198172 ↗
L2aSR_OBSCited in: Epidemiology and Risk Factors, Pathophysiology - [40]
Moscona-Nissan A, López-Hernández JC, González-Morales AP. “Mirtazapine Risk of Hyponatremia and Syndrome of Inappropriate Antidiuretic Hormone Secretion in Adult and Elderly Patients: A Systematic Review.” Cureus (2021). PMID: 35141079 ↗
L2aSR_OBSCited in: Epidemiology and Risk Factors, Etiology - [41]
Anastassopoulou C, Panagiotopoulos AP, Ferous S et al.. “RSV vaccines and Guillain-Barré syndrome: Insights into an emerging concern.” Vaccine (2025). PMID: 40466480 ↗
L5REVIEW_NARRATIVECited in: Epidemiology and Risk Factors, Complications and Prognosis - [42]
Dang S, Zhang S, Zhao J et al.. “The syndrome of inappropriate antidiuretic hormone associated with nasal and paranasal malignant tumors.” European archives of oto-rhino-laryngology : official journal of the European Federation of Oto-Rhino-Laryngological Societies (EUFOS) : affiliated with the German Society for Oto-Rhino-Laryngology - Head and Neck Surgery (2024). PMID: 38163817 ↗
L5OTHERCited in: Epidemiology and Risk Factors, Diagnostic Criteria, Management - [43]
Maesaka JK, Imbriano LJ, Grant C et al.. “High prevalence of renal salt wasting induced by haptoglobin-related protein without signal peptide is linked to new syndrome of salt wasting in Alzheimer disease.” Kidney research and clinical practice (2024). PMID: 37919890 ↗
L5OTHERCited in: Epidemiology and Risk Factors, Differential Diagnosis - [44]
Akaishi T, Tarasawa K, Matsumoto Y et al.. “Associations between neuromyelitis optica spectrum disorder, Sjögren's syndrome, and conditions with electrolyte disturbances.” Journal of the neurological sciences (2023). PMID: 37515845 ↗
L5OTHERCited in: Epidemiology and Risk Factors - [45]
Naimi B, Duffy A, Garvey E et al.. “Trends in Endoscopic and Microscopic Approaches to Transsphenoidal Pituitary Surgery in the US.” The Laryngoscope (2023). PMID: 37318105 ↗
L5OTHERCited in: Epidemiology and Risk Factors, Special Populations - [46]
Charalambous LT, Adil SM, Rajkumar S et al.. “A Nationwide Analysis of Aneurysmal Subarachnoid Hemorrhage Mortality, Complications, and Health Economics in the USA.” Translational stroke research (2023). PMID: 35881231 ↗
L5OTHERCited in: Epidemiology and Risk Factors, Complications and Prognosis, Special Populations - [47]
Roser P, Mende KC, Dimitriadis GK et al.. “The Potential of Self-Assessment and Associated Factors for Delayed Symptomatic Hyponatremia Following Transsphenoidal Surgery: A Single Center Experience.” Journal of clinical medicine (2022). PMID: 36615106 ↗
L5OTHERCited in: Epidemiology and Risk Factors - [48]
Maesaka JK, Imbriano LJ, Grant C et al.. “New Approach to Hyponatremia: High Prevalence of Cerebral/Renal Salt Wasting, Identification of Natriuretic Protein That Causes Salt Wasting.” Journal of clinical medicine (2022). PMID: 36556061 ↗
L5REVIEW_NARRATIVECited in: Epidemiology and Risk Factors, Laboratory Workup and Imaging, Differential Diagnosis - [49]
Sumisławski P, Piffko A, Huckhagel T et al.. “Exoscopic vs. microscopic transsphenoidal surgery for Cushing's disease: a retrospective single-center study on 388 patients.” Neurosurgical review (2022). PMID: 36136255 ↗
L5OTHERCited in: Epidemiology and Risk Factors, Special Populations - [50]
Léveillé E, Aljassar M, Beland B et al.. “Determinants of hyponatremia following a traumatic brain injury.” Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology (2022). PMID: 35037099 ↗
L5OTHERCited in: Epidemiology and Risk Factors, Differential Diagnosis - [51]
Chang MT, Jitaroon K, Song S et al.. “Venous thromboembolism rates and risk factors following endoscopic skull base surgery.” International forum of allergy & rhinology (2022). PMID: 34894093 ↗
L5OTHERCited in: Epidemiology and Risk Factors, Etiology, Special Populations - [52]
Kennedy GT, Sande CM, Surrey LF et al.. “Anterior Mediastinal Neuroblastoma Associated with Syndrome of Inappropriate Antidiuretic Hormone Secretion: A Morphologic, Immunohistochemical, and Genetic Case Report and Review of the Literature.” International journal of surgical pathology (2022). PMID: 35188820 ↗
L4CASE_REPORTCited in: Epidemiology and Risk Factors - [53]
Pinkhasov A, Xiong G, Bourgeois JA et al.. “Management of SIADH-related hyponatremia due to psychotropic medications - An expert consensus from the Association of Medicine and Psychiatry.” Journal of psychosomatic research (2021). PMID: 34739943 ↗
L5OTHERCited in: Epidemiology and Risk Factors, Etiology - [54]
Coupaye M, Pellikaan K, Goldstone AP et al.. “Hyponatremia in Children and Adults with Prader-Willi Syndrome: A Survey Involving Seven Countries.” Journal of clinical medicine (2021). PMID: 34441851 ↗
L5OTHERCited in: Epidemiology and Risk Factors - [55]
Sorba EL, Staartjes VE, Voglis S et al.. “Diabetes insipidus and syndrome of inappropriate antidiuresis (SIADH) after pituitary surgery: incidence and risk factors.” Neurosurgical review (2021). PMID: 32583307 ↗
L5OTHERCited in: Epidemiology and Risk Factors - [56]
Wu R, Li C, Wang Z et al.. “A narrative review of progress in diagnosis and treatment of small cell lung cancer patients with hyponatremia.” Translational lung cancer research (2020). PMID: 33489807 ↗
L5REVIEW_NARRATIVECited in: Epidemiology and Risk Factors - [57]
Bao S, Qin L, Zhang Y et al.. “Refractory hyponatremia in small cell lung cancer: a case report and literature review.” Frontiers in endocrinology (2026). PMID: 41890180 ↗
L4CASE_REPORTCited in: Etiology, Management - [58]
Ren P, Yang Q. “The role of tolvaptan in managing hyponatremia in small cell lung cancer patients with SIADH: a retrospective study of 23 cases.” Translational cancer research (2021). PMID: 35116450 ↗
L2bCOHORTCited in: Etiology, Complications and Prognosis - [59]
Mannheimer B, Lindh JD, Fahlén CB et al.. “Drug-induced hyponatremia in clinical care.” European journal of internal medicine (2025). PMID: 40328519 ↗
L5REVIEW_NARRATIVECited in: Etiology - [60]
Rosner MH, Rondon-Berrios H, Sterns RH. “Syndrome of Inappropriate Antidiuresis.” Journal of the American Society of Nephrology : JASN (2025). PMID: 39621420 ↗
L5REVIEW_NARRATIVECited in: Etiology, Clinical Features, Management - [61]
Tao S, Guo S, Tong N. “Update on the clinical applications of SGLTis: Insight to benefits beyond hypoglycemic and cardiorenal protection.” Pharmacotherapy (2024). PMID: 38973479 ↗
L5REVIEW_NARRATIVECited in: Etiology - [62]
Warren AM, Grossmann M, Christ-Crain M et al.. “Syndrome of Inappropriate Antidiuresis: From Pathophysiology to Management.” Endocrine reviews (2023). PMID: 36974717 ↗
L5REVIEW_NARRATIVECited in: Etiology, Differential Diagnosis - [63]
Kim GH. “Pathophysiology of Drug-Induced Hyponatremia.” Journal of clinical medicine (2022). PMID: 36233678 ↗
L5REVIEW_NARRATIVECited in: Etiology, Pathophysiology - [64]
Noda Y, Sasaki S. “Updates and Perspectives on Aquaporin-2 and Water Balance Disorders.” International journal of molecular sciences (2021). PMID: 34884753 ↗
L5REVIEW_NARRATIVECited in: Etiology, Pathophysiology - [65]
Jiang Z, Qu X, Yan Z et al.. “Case Report: Severe SIADH and QTc prolongation induced by escitalopram-quetiapine interaction in a CYP2C19 intermediate metabolizer at therapeutic doses.” Frontiers in pharmacology (2026). PMID: 41693783 ↗
L4CASE_REPORTCited in: Etiology - [66]
Menzi S, Jaramillo SD, Pfister S et al.. “Case report: Secondary failure to tolvaptan in a patient with SCLC and paraneoplastic SIADH.” Frontiers in endocrinology (2024). PMID: 38803472 ↗
L4CASE_REPORTCited in: Etiology, Pathophysiology, Laboratory Workup and Imaging, Management - [67]
Takenouchi H, Anno T, Kimura Y et al.. “Case Report: A Patient With Neuroleptic Malignant Syndrome, Water Intoxication and Hyponatremia Associated With Severe Cerebral Edema and Coma.” Frontiers in endocrinology (2022). PMID: 35360072 ↗
L4CASE_REPORTCited in: Etiology, Differential Diagnosis - [68]
Saffarzadeh M, Alim BM, Hernaiz-Leonardo JC et al.. “Syndrome of Inappropriate Antidiuretic Hormone Release Secondary to Ectopic Olfactory Neuroblastoma: Case Report and Review of Literature.” Ear, nose, & throat journal (2025). PMID: 37776288 ↗
L4CASE_REPORTCited in: Etiology, Special Populations - [69]
Haymann JP. “Drug-induced syndrome of inappropriate diuresis or of antidiuretic hormone secretion?” Annales d'endocrinologie (2023). PMID: 36965851 ↗
L5REVIEW_NARRATIVECited in: Etiology, Pathophysiology - [70]
Mo H, Channa Y, Ferrara TM et al.. “Hyponatremia Associated with the Use of Common Antidepressants in the All of Us Research Program.” Clinical pharmacology and therapeutics (2025). PMID: 39540435 ↗
L5OTHERCited in: Etiology - [71]
Li X, Xu T, Jian X. “Advanced small cell lung cancer with severe hyponatremia: a case report and literature review.” Frontiers in oncology (2025). PMID: 41018077 ↗
L4CASE_REPORTCited in: Etiology, Clinical Features, Management - [72]
Sato A, Yasui-Furukori N, Oda Y et al.. “Asymptomatic syndrome of inappropriate secretion of antidiuretic hormone (SIADH) following duloxetine treatment for pain with depression: Two case reports.” Neuropsychopharmacology reports (2022). PMID: 35733329 ↗
L4CASE_REPORTCited in: Etiology - [73]
Ayoola A, Sodji QH, Chin S et al.. “Syndrome of inappropriate secretion of antidiuretic hormone following high dose rate brachytherapy for prostate cancer: a case report.” BMC urology (2022). PMID: 35272646 ↗
L4CASE_REPORTCited in: Etiology - [74]
Kacperczyk J, Perdyan A, Stompór M. “Drug-Resistant Hyponatremia after Escitalopram Intake: A Series of Two Case Reports.” Annals of geriatric medicine and research (2021). PMID: 34610667 ↗
L4CASE_REPORTCited in: Etiology - [75]
Saillant A, Try M, Laparra A et al.. “[Electrolyte disorders in oncological patients].” Bulletin du cancer (2024). PMID: 37208250 ↗
L5REVIEW_NARRATIVECited in: Etiology - [76]
Poch E, Molina A, Piñeiro G. “Syndrome of inappropriate antidiuretic hormone secretion.” Medicina clinica (2022). PMID: 35659417 ↗
L5REVIEW_NARRATIVECited in: Etiology, Diagnostic Criteria - [77]
Bathula S, Pasupuleti H, Waqar A et al.. “Escaped surveillance: tuberculosis masked by severe hyponatremia in an immunocompromised patient: a case report.” Journal of medical case reports (2026). PMID: 41882752 ↗
L4CASE_REPORTCited in: Etiology, Clinical Features - [78]
Rupasinghe S, Lemoh C. “Post-traumatic cerebral venous sinus thrombosis complicated with syndrome of inappropriate antidiuretic hormone secretion: a case report.” Journal of medical case reports (2025). PMID: 40091110 ↗
L4CASE_REPORTCited in: Etiology, Differential Diagnosis - [79]
Warren AM, Grossmann M, Hoermann R et al.. “Tolvaptan vs Fluid Restriction in Moderate-Profound Hyponatremia: An Open-Label Randomized Clinical Trial.” The Journal of clinical endocrinology and metabolism (2026). PMID: 40720585 ↗
L1bRCTCited in: Pathophysiology, Clinical Features, Management, Complications and Prognosis - [80]
Kaur K, Venkatachalapathi S, Mumtaz M et al.. “Decoding Hyponatremia: A Systematic Review of Diagnostic Pathways and Therapeutic Approaches Applied When Correction Fails.” Cureus (2025). PMID: 41357015 ↗
L2aSR_OBSCited in: Pathophysiology, Management - [81]
Kamran N, Mohammad M. “SGLT2 Inhibitors as a Novel Therapeutic Strategy in SIADH-Induced Hyponatraemia: Emerging Evidence and Clinical Implications.” Journal of clinical medicine (2026). PMID: 41899044 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology, Management - [82]
Moodley N. “Copeptin analysis in endocrine disorders.” Frontiers in endocrinology (2023). PMID: 37859988 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology, Laboratory Workup and Imaging, Differential Diagnosis - [83]
Koundal H, Dhandapani M, Thakur P et al.. “Effectiveness of dietary diabetes insipidus bundle on the severity of postoperative fluid imbalance in pituitary region tumours: A randomized controlled trial.” Journal of advanced nursing (2021). PMID: 34028859 ↗
L1bRCTCited in: Pathophysiology, Special Populations - [84]
Driano JE, Lteif AN, Creo AL. “Vasopressin-Dependent Disorders: What Is New in Children?” Pediatrics (2021). PMID: 33795481 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology, Laboratory Workup and Imaging, Special Populations - [85]
Castle-Kirszbaum M, Kyi M, Wright C et al.. “Hyponatraemia and hypernatraemia: Disorders of Water Balance in Neurosurgery.” Neurosurgical review (2021). PMID: 33389341 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology, Laboratory Workup and Imaging, Complications and Prognosis - [86]
Seay NW, Lehrich RW, Greenberg A. “Diagnosis and Management of Disorders of Body Tonicity-Hyponatremia and Hypernatremia: Core Curriculum 2020.” American journal of kidney diseases : the official journal of the National Kidney Foundation (2020). PMID: 31606238 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology - [87]
Sasidharan Pillai S, Boxerman JL, Groblewski JC et al.. “An adolescent girl with syndrome of inappropriate antidiuretic hormone secretion preceding the diagnosis of olfactory neuroblastoma - a case report.” Frontiers in endocrinology (2024). PMID: 39479268 ↗
L4CASE_REPORTCited in: Pathophysiology, Clinical Features, Management - [88]
Jones B, Corredor M, Lteif A et al.. “Use of Copeptin Levels to Predict the Resolution of Transient Postoperative SIADH.” Hormone research in paediatrics (2020). PMID: 32998133 ↗
L4CASE_REPORTCited in: Pathophysiology, Laboratory Workup and Imaging, Special Populations - [89]
Li L, Guo Y, Chen C et al.. “Mechanisms of hyponatremia and diabetes insipidus after acute spinal cord injury: a critical review.” Chinese neurosurgical journal (2023). PMID: 37968769 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology, Clinical Features, Differential Diagnosis - [90]
Praharaj DL, Anand AC. “Clinical Implications, Evaluation, and Management of Hyponatremia in Cirrhosis.” Journal of clinical and experimental hepatology (2022). PMID: 35535075 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology, Laboratory Workup and Imaging - [91]
Misra UK, Kalita J. “Mechanism, spectrum, consequences and management of hyponatremia in tuberculous meningitis.” Wellcome open research (2019). PMID: 32734004 ↗
L5REVIEW_NARRATIVECited in: Pathophysiology, Diagnostic Criteria, Laboratory Workup and Imaging - [92]
Bogusz-Wójcik A, Rakusiewicz-Krasnodębska K, Hautz W et al.. “Correlation Between Endocrine and Other Clinical Factors with Peripapillary Retinal Nerve Fiber Layer Thickness After Surgical Treatment of Pediatric Craniopharyngioma.” Biomedicines (2026). PMID: 41595773 ↗
L5OTHERCited in: Pathophysiology, Special Populations - [93]
Desai S, Holsaeter K, Winski A et al.. “Safety and Efficacy of Tolvaptan for Acute Refractive Hyponatremia Associated with Traumatic Brain Injury.” Journal of clinical medicine (2025). PMID: 40943898 ↗
L5OTHERCited in: Pathophysiology, Management, Complications and Prognosis - [94]
Gibbons J, Dreimane D. “The Utility of Copeptin Measurement in Hospitalized Pediatric Patients with Syndrome of Inappropriate Antidiuretic Secretion.” Hormone research in paediatrics (2025). PMID: 40544834 ↗
L5OTHERCited in: Pathophysiology, Laboratory Workup and Imaging - [95]
Estephan K, Charbonneau L, Chennou F et al.. “The surgical management of Cushing disease: a case series from a Canadian tertiary center.” Neurological research (2025). PMID: 41433699 ↗
L4CASE_REPORTCited in: Pathophysiology - [96]
Dong C, Zhu B, Miao G et al.. “Case Report: One case of pregnancy complicated by large cell neuroendocrine carcinoma of the cervix with syndrome of inappropriate secretion of antidiuretic hormone.” Frontiers in oncology (2025). PMID: 41395606 ↗
L4CASE_REPORTCited in: Pathophysiology, Management, Complications and Prognosis - [97]
Johnson RJ, Lee SMK, Sánchez-Lozada LG et al.. “Fructose: A New Variable to Consider in SIADH and the Hyponatremia Associated With Long-Distance Running?” American journal of kidney diseases : the official journal of the National Kidney Foundation (2023). PMID: 36940740 ↗
L5OTHERCited in: Pathophysiology, Complications and Prognosis, Special Populations - [98]
Zhang D, Yong W, Movassaghi M et al.. “Whole Exome Sequencing Identifies PHF14 Mutations in Neurocytoma and Predicts Responsivity to the PDGFR Inhibitor Sunitinib.” Biomedicines (2022). PMID: 36359362 ↗
L5OTHERCited in: Pathophysiology - [99]
Hussein Z, Tzoulis P, Marcus HJ et al.. “The management and outcome of hyponatraemia following transsphenoidal surgery: a retrospective observational study.” Acta neurochirurgica (2022). PMID: 35079890 ↗
L5OTHERCited in: Pathophysiology, Special Populations - [100]
Puma A, Brugnara M, Cavarzere P et al.. “Case Report: Long-Term Tolvaptan Treatment in a Child With SIADH and Suprasellar Arachnoid Cyst.” Frontiers in pediatrics (2021). PMID: 34336740 ↗
L4CASE_REPORTCited in: Pathophysiology - [101]
Hiroshima S, Nyuzuki H, Sasaki S et al.. “Regulation of Serum Sodium Levels during Chemotherapy Using Selective Arginine Vasopressin V2-Receptor Antagonist Tolvaptan in a Four-Year-Old Girl with a Suprasellar Germ Cell Tumor.” Children (Basel, Switzerland) (2021). PMID: 33920088 ↗
L4CASE_REPORTCited in: Pathophysiology - [102]
Verrienti M, Marino Picciola V, Ambrosio MR et al.. “Pituitary and COVID-19 vaccination: a systematic review.” Pituitary (2024). PMID: 38761322 ↗
L2aSR_OBSCited in: Clinical Features - [103]
Chen KQ, Liu X, Lei HB. “Case Report: Syndrome of inappropriate antidiuretic hormone secretion induced by pramipexole: a case report and literature review.” Frontiers in pharmacology (2025). PMID: 40894224 ↗
L4CASE_REPORTCited in: Clinical Features - [104]
McCoin N, Marcum S, Martin J. “Case report: Hyponatremia due to syndrome of inappropriate antidiuresis associated with normal pressure hydrocephalus.” The American journal of emergency medicine (2025). PMID: 40187989 ↗
L4CASE_REPORTCited in: Clinical Features - [105]
Lee S, Seo HW, Lee J et al.. “Unusual Presentation of Hyponatremia: Persistent Hiccups.” Electrolyte & blood pressure : E & BP (2025). PMID: 41541563 ↗
L4CASE_REPORTCited in: Clinical Features, Differential Diagnosis, Management - [106]
Żak-Skryśkiewicz Z, Krupińska P, Bieńkowski C et al.. “Hyponatremia Due to VZV-Induced SIADH in an Older Patient: Case Report and Literature Review.” Infectious disease reports (2025). PMID: 40981326 ↗
L4CASE_REPORTCited in: Clinical Features - [107]
Spasovski G. “Hyponatraemia-treatment standard 2024.” Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (2024). PMID: 39009016 ↗
L5REVIEW_NARRATIVECited in: Clinical Features, Management, Complications and Prognosis - [108]
Sasaki T, Shindo Y, Kikuchi K et al.. “Vortioxetine-induced syndrome of inappropriate secretion of antidiuretic hormone: A case report.” Neuropsychopharmacology reports (2024). PMID: 38588007 ↗
L4CASE_REPORTCited in: Clinical Features - [109]
Tzoulis P, Yavropoulou MP. “Association of hyponatremia with bone mineral density and fractures: a narrative review.” Therapeutic advances in endocrinology and metabolism (2023). PMID: 37736657 ↗
L5REVIEW_NARRATIVECited in: Clinical Features - [110]
Than Aye T, Sein MT, Thiha P et al.. “Changes in Urinary Aquaporin 2 and Serum Sodium After Catheterization in Elderly Patients with Syndrome of Inappropriate Antidiuretic Hormone and Urinary Retention: A Preliminary Hospital-based Study in Yangon, Myanmar.” TouchREVIEWS in endocrinology (2025). PMID: 40485652 ↗
L5OTHERCited in: Clinical Features, Management - [111]
Soga K, Suzuki Y, Hayakawa F et al.. “Recurrent Severe Hyponatremia Following Polyethylene Glycol Electrolyte Lavage Solution with Ascorbic Acid in a Patient with Undiagnosed Syndrome of Inappropriate Antidiuretic Hormone Secretion.” The American journal of case reports (2025). PMID: 40760784 ↗
L4CASE_REPORTCited in: Clinical Features - [112]
Lauzon I, deGuerké L, Fortin S et al.. “Small cell carcinoma of the cervix with syndrome of inappropriate antidiuretic hormone secretion following chemotherapy: A case report and literature review.” Gynecologic oncology reports (2025). PMID: 40092736 ↗
L4CASE_REPORTCited in: Clinical Features, Differential Diagnosis - [113]
Arieff AI, Gabbai R, Goldfine ID. “Cerebral Salt-Wasting Syndrome: Diagnosis by Urine Sodium Excretion.” The American journal of the medical sciences (2017). PMID: 29078838 ↗
L2bTRIAL_NONRANDOMCited in: Diagnostic Criteria - [114]
James V, Nimkoff L. “Multiphase management of sodium imbalance following traumatic brain injury: a case-based review.” BMC pediatrics (2025). PMID: 40730974 ↗
L4CASE_REPORTCited in: Diagnostic Criteria - [115]
Bardanzellu F, Pintus MC, Masile V et al.. “Focus on neonatal and infantile onset of nephrogenic syndrome of inappropriate antidiuresis: 12 years later.” Pediatric nephrology (Berlin, Germany) (2019). PMID: 29546600 ↗
L5REVIEW_NARRATIVECited in: Diagnostic Criteria - [116]
Tuli G, Tessaris D, Einaudi S et al.. “Tolvaptan Treatment in Children with Chronic Hyponatremia due to Inappropriate Antidiuretic Hormone Secretion: A Report of Three Cases.” Journal of clinical research in pediatric endocrinology (2017). PMID: 28515029 ↗
L4CASE_REPORTCited in: Diagnostic Criteria - [117]
Saraceno E, Serra I, Bracci B et al.. “SIADH as an Underrecognized Manifestation of Porphyria-like Crises in Hereditary Tyrosinemia Type 1: Clinical and Pathophysiological Insights.” International journal of molecular sciences (2026). PMID: 41596311 ↗
L4CASE_REPORTCited in: Diagnostic Criteria, Laboratory Workup and Imaging - [118]
Sekhon SS, Taha K, Kim LH et al.. “A Pediatric Case of Reninoma Presenting with Paraneoplastic Syndrome of Inappropriate Antidiuretic Hormone Secretion.” Hormone research in paediatrics (2024). PMID: 38052189 ↗
L4CASE_REPORTCited in: Diagnostic Criteria - [119]
Takano M, Okada T, Kobayashi T et al.. “Syndrome of inappropriate antidiuretic hormone secretion induced by suvorexant: a case report.” Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine (2021). PMID: 33141013 ↗
L4CASE_REPORTCited in: Diagnostic Criteria - [120]
Babayev R, Terner S, Chandra S et al.. “Trimethoprim-associated hyponatremia.” American journal of kidney diseases : the official journal of the National Kidney Foundation (2013). PMID: 23891358 ↗
L4CASE_REPORTCited in: Diagnostic Criteria - [121]
Kawahara T, Toda M, Kanagawa M et al.. “Etiology and Clinical Features of Patients With Hyponatremia in the Emergency Department: A Cross-sectional Study.” The Journal of clinical endocrinology and metabolism (2025). PMID: 40130271 ↗
L5OTHERCited in: Diagnostic Criteria, Laboratory Workup and Imaging, Differential Diagnosis - [122]
Decaux G, Musch W. “The Urine Calcium/Creatinine Ratio and Uricemia during Hyponatremia of Different Origins: Clinical Implications.” Journal of clinical medicine (2023). PMID: 36675652 ↗
L5OTHERCited in: Diagnostic Criteria, Laboratory Workup and Imaging, Differential Diagnosis - [123]
Fenske W, Allolio B. “The syndrome of inappropriate secretion of antidiuretic hormone: diagnostic and therapeutic advances.” Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme (2010). PMID: 20607641 ↗
L5REVIEW_NARRATIVECited in: Diagnostic Criteria - [124]
Ausiello JC, Bruce JN, Freda PU. “Postoperative assessment of the patient after transsphenoidal pituitary surgery.” Pituitary (2008). PMID: 18320327 ↗
L5REVIEW_NARRATIVECited in: Diagnostic Criteria - [125]
Fenske W, Störk S, Koschker AC et al.. “Value of fractional uric acid excretion in differential diagnosis of hyponatremic patients on diuretics.” The Journal of clinical endocrinology and metabolism (2008). PMID: 18477658 ↗
L5OTHERCited in: Diagnostic Criteria - [126]
Siegel AJ, Verbalis JG, Clement S et al.. “Hyponatremia in marathon runners due to inappropriate arginine vasopressin secretion.” The American journal of medicine (2007). PMID: 17466660 ↗
L5OTHERCited in: Diagnostic Criteria - [127]
Siegel AJ. “Hypertonic (3%) sodium chloride for emergent treatment of exercise-associated hypotonic encephalopathy.” Sports medicine (Auckland, N.Z.) (2007). PMID: 17465635 ↗
L5OTHERCited in: Diagnostic Criteria - [128]
Hiramatsu R, Takeshita A, Taguchi M et al.. “Symptomatic hyponatremia after voluntary excessive water ingestion in a patient without psychiatric problems.” Endocrine journal (2007). PMID: 17641442 ↗
L4CASE_REPORTCited in: Diagnostic Criteria - [129]
Tamura T, Taniguchi N, Otsuki K et al.. “[A Case of Consciousness Disorder Induced by the Syndrome of Inappropriate Antidiuretic Hormone Secretion Following Cisplatin and 5-Fluorouracil Chemotherapy in a Patient with Tongue Cancer].” Gan to kagaku ryoho. Cancer & chemotherapy (2018). PMID: 30026451 ↗
L4CASE_REPORTCited in: Diagnostic Criteria - [130]
Seay HL, Khallouf L, Lieberman A et al.. “An Unusual Case of Neurosyphilis Manifesting as Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH).” The American journal of case reports (2021). PMID: 33589580 ↗
L4CASE_REPORTCited in: Diagnostic Criteria - [131]
Karakuchi N, Ohmori I, Inoue M et al.. “Inappropriate Secretion of Antidiuretic Hormone after Pancreatoduodenectomy for Pancreatic Head Cancer: A Case Report and Literature Review.” Case reports in oncology (2021). PMID: 33776694 ↗
L4CASE_REPORTCited in: Diagnostic Criteria - [132]
Al-Hinai A, Al-Murshedi F, Al-Nabhani D et al.. “Syndrome of Inappropriate Antidiuretic Hormone Secretion in a Patient with Uncontrolled Tyrosinaemia Type 1.” Sultan Qaboos University medical journal (2021). PMID: 34221482 ↗
L4CASE_REPORTCited in: Diagnostic Criteria - [133]
Kang SG, Choi SH, Kim HY et al.. “Low-dose Quetiapine-induced Syndrome of Inappropriate Antidiuretic Hormone in a Patient with Traumatic Brain Syndrome.” Clinical psychopharmacology and neuroscience : the official scientific journal of the Korean College of Neuropsychopharmacology (2020). PMID: 31958918 ↗
L5OTHERCited in: Diagnostic Criteria - [134]
Kleindienst A, Georgiev S, Schlaffer SM et al.. “Tolvaptan Versus Fluid Restriction in the Treatment of Hyponatremia Resulting from SIADH Following Pituitary Surgery.” Journal of the Endocrine Society (2020). PMID: 32666012 ↗
L5OTHERCited in: Diagnostic Criteria - [135]
Patil SM, Beck PP, Patel TP et al.. “Cytomegalovirus pneumonitis-induced secondary hemophagocytic lymphohistiocytosis and SIADH in an immunocompetent elderly male literature review.” IDCases (2020). PMID: 33024698 ↗
L4CASE_REPORTCited in: Diagnostic Criteria - [136]
Assadi F. “Diagnostic Utility of Fractional Excretion of Urate, Urinary Phosphate and Brain Natriuretic Peptide in Distinguishing Cerebral/Renal Salt Wasting From SIADH in Neurologically Ill Children: A Systematic Review.” Clinical endocrinology (2026). PMID: 41058069 ↗
L2aSR_OBSCited in: Laboratory Workup and Imaging - [137]
Berend K, Heldeweg MLA. “The role of the clinical laboratory in diagnosing hyponatremia disorders.” Critical reviews in clinical laboratory sciences (2025). PMID: 40022565 ↗
L5REVIEW_NARRATIVECited in: Laboratory Workup and Imaging, Differential Diagnosis - [138]
Gadoth A, Nisnboym M, Alcalay Y et al.. “Electrolyte Imbalance in Anti-LGI1 Encephalitis: It Is Not All in Your Head.” Neurology(R) neuroimmunology & neuroinflammation (2023). PMID: 37591767 ↗
L5REVIEW_NARRATIVECited in: Laboratory Workup and Imaging - [139]
Lindner G, Ryser B. “The syndrome of inappropriate antidiuresis after vaccination against COVID-19: case report.” BMC infectious diseases (2021). PMID: 34560836 ↗
L4CASE_REPORTCited in: Laboratory Workup and Imaging - [140]
Yang F, Cao Z, Wang X et al.. “A multi-parameter study of the etiological diagnosis of hyponatremia after hypothalamic tumor surgery.” Clinical neurology and neurosurgery (2021). PMID: 34715556 ↗
L5REVIEW_NARRATIVECited in: Laboratory Workup and Imaging, Special Populations - [141]
Săcărescu A, Turliuc MD, Brănișteanu DD. “Role of copeptin in the diagnosis of traumatic neuroendocrine dysfunction.” Neuropeptides (2021). PMID: 34175655 ↗
L5REVIEW_NARRATIVECited in: Laboratory Workup and Imaging - [142]
Douglas A, Baborie A. “Inappropriate antidiuretic hormone secretion in amyotrophic lateral sclerosis.” Clinical neuropathology (2020). PMID: 32449677 ↗
L4CASE_REPORTCited in: Laboratory Workup and Imaging, Special Populations - [143]
Li N, Zhang H, Wang S et al.. “Urea transporter UT-A1 as a novel drug target for hyponatremia.” FASEB journal : official publication of the Federation of American Societies for Experimental Biology (2024). PMID: 38924449 ↗
L5OTHERCited in: Laboratory Workup and Imaging, Management - [144]
Adin DB, Levinzon I, Harris AN. “Long-term Outcome of a Chihuahua With Idiopathic Syndrome of Inappropriate Antidiuretic Hormone Secretion.” Journal of the American Animal Hospital Association (2024). PMID: 39480739 ↗
L4CASE_REPORTCited in: Laboratory Workup and Imaging, Differential Diagnosis - [145]
Potasso L, Monnerat S, Refardt J et al.. “Chloride and Potassium Assessment Is a Helpful Tool for Differential Diagnosis of Thiazide-Associated Hyponatremia.” The Journal of clinical endocrinology and metabolism (2023). PMID: 36899489 ↗
L5OTHERCited in: Laboratory Workup and Imaging, Differential Diagnosis - [146]
Moon RJ, Soliman M, Hoogenboom L et al.. “Syndrome of inappropriate secretion of anti-diuretic hormone due to hypothalamic hamartoma: use of tolvaptan.” Journal of pediatric endocrinology & metabolism : JPEM (2023). PMID: 37327191 ↗
L4CASE_REPORTCited in: Laboratory Workup and Imaging - [147]
Oshima M, Fukuhara J, Noto T et al.. “A Case of Kawasaki Disease Complicated With Cerebral Salt-Wasting Syndrome.” Frontiers in pediatrics (2020). PMID: 32766177 ↗
L4CASE_REPORTCited in: Laboratory Workup and Imaging - [148]
Vera-Cáceres CH, García-Huguet M, Gil de Genover A et al.. “Dysautonomia after COVID-19 infection: A case report.” Neurologia (2026). PMID: 41579008 ↗
L4CASE_REPORTCited in: Laboratory Workup and Imaging - [149]
Švitek L, Grubišić B, Schonberger E et al.. “Syndrome of inappropriate antidiuretic hormone secretion as an adverse reaction of ciprofloxacin: a case report and literature review.” Biochemia medica (2024). PMID: 38125612 ↗
L4CASE_REPORTCited in: Laboratory Workup and Imaging - [150]
Dong QW, Tang L, Ge DD et al.. “A case of linezolid-induced SIADH in elderly and a review of the literature.” European review for medical and pharmacological sciences (2022). PMID: 36066143 ↗
L4CASE_REPORTCited in: Laboratory Workup and Imaging - [151]
Wu J, Yan Z, Li B et al.. “Pituitary Apoplexy-associated Cerebral Salt Wasting Syndrome: A Case Report and Literature Review.” Clinical therapeutics (2023). PMID: 37778916 ↗
L4CASE_REPORTCited in: Differential Diagnosis - [152]
Imbriano LJ, Grant C, Masani N. “The Different Paths That Lead to Hypotonic Hyponatremia, and a Safe Approach to Treatment.” Journal of clinical medicine (2024). PMID: 39797178 ↗
L5REVIEW_NARRATIVECited in: Differential Diagnosis - [153]
Busl KM, Rabinstein AA. “Prevention and Correction of Dysnatremia After Aneurysmal Subarachnoid Hemorrhage.” Neurocritical care (2023). PMID: 37138158 ↗
L5REVIEW_NARRATIVECited in: Differential Diagnosis - [154]
Makino E, Hashimoto T, Sako A et al.. “Comparison of severe hyponatremia in patients with and without psychiatric diseases: A single-center retrospective study.” PCN reports : psychiatry and clinical neurosciences (2023). PMID: 38868403 ↗
L2bCOHORTCited in: Differential Diagnosis, Complications and Prognosis - [155]
Netto AB, Chandrahasa N, Koshy SS et al.. “Hyponatremia in Guillain-Barre Syndrome: A Review of Its Pathophysiology and Management.” The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques (2025). PMID: 38361453 ↗
L5REVIEW_NARRATIVECited in: Differential Diagnosis, Complications and Prognosis - [156]
Klimek M, de Smalen P, Janssen J. “Hyperlactatemia and other perioperative metabolic disturbances in neuroanesthesia.” Current opinion in anaesthesiology (2022). PMID: 35942723 ↗
L5REVIEW_NARRATIVECited in: Differential Diagnosis - [157]
Naganuma J, Koyama S, Watabe Y et al.. “A Boy with Reset Osmostat Who Developed Chronic Hyponatremia due to Hypothalamic Injury Caused By a Giant Arachnoid Cyst.” Journal of clinical research in pediatric endocrinology (2024). PMID: 36794751 ↗
L4CASE_REPORTCited in: Differential Diagnosis - [158]
Banerjee S, George A, Bala A et al.. “Assessing the Role of Delta Copeptin in the Evaluation of SIAD and CSW.” Indian journal of pediatrics (2026). PMID: 41563654 ↗
L5OTHERCited in: Differential Diagnosis - [159]
Alvarado-Torres MT, España Arrieta H, Davidson JS et al.. “Refractory hyponatremia solved through early cranioplasty after decompressive hemicraniectomy in a traumatic brain injury patient: a case report.” Brain injury (2026). PMID: 41718483 ↗
L4CASE_REPORTCited in: Differential Diagnosis - [160]
Yamichannaiah C, Sheth KV, Lila AR et al.. “Management of water and electrolyte disorders post-pituitary adenoma surgery: experience with Tolvaptan 7.5 mg at a tertiary care centre.” Pituitary (2025). PMID: 41148440 ↗
L5OTHERCited in: Differential Diagnosis, Management - [161]
Perschinka F, Köglberger P, Klein SJ et al.. “[Hyponatremia : Etiology, diagnosis and acute therapy].” Medizinische Klinik, Intensivmedizin und Notfallmedizin (2023). PMID: 37646802 ↗
L5OTHERCited in: Differential Diagnosis - [162]
Kamel MH, Upadhyay A, Borkan SC. “Intractable hyponatremia complicated by a reset osmostat: a case report.” Journal of medical case reports (2023). PMID: 36639685 ↗
L4CASE_REPORTCited in: Differential Diagnosis - [163]
Lewellyn D, Nuamek T, Ostarijas E et al.. “Low-Dose Tolvaptan for the Treatment of Syndrome of Inappropriate Antidiuretic Hormone-Associated Hyponatremia: A Systematic Review, Meta-Analysis, and Meta-Regression Analysis of Clinical Effectiveness and Safety.” Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists (2025). PMID: 40288608 ↗
L2aSR_OBSCited in: Management, Complications and Prognosis - [164]
Llewellyn DC, Oštarijaš E, Sahadevan S et al.. “Efficacy and Safety of Low-Dose Tolvaptan (7.5 mg) in the Treatment of Inpatient Hyponatremia: A Retrospective Study.” Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists (2025). PMID: 39733944 ↗
L2bCOHORTCited in: Management, Complications and Prognosis - [165]
Hagiwara D, Matsukawa M, Tasaki J et al.. “A retrospective study on tolvaptan prescription in clinical practice in patients with syndrome of inappropriate secretion of antidiuretic hormone (SIADH) using the Japanese claims database.” Endocrine journal (2023). PMID: 37914256 ↗
L2bCOHORTCited in: Management - [166]
Li J, Yang Z, Wang K et al.. “Syndrome of inappropriate antidiuretic hormone secretion following extensively drug-resistant Klebsiella pneumoniae associated with complicated urinary tract infection: a case report.” Frontiers in medicine (2025). PMID: 40636392 ↗
L4CASE_REPORTCited in: Management - [167]
Martínez González Á, González Nunes M, Rodeiro Escobar P et al.. “[Tolvaptan versus fluid restriction in the treatment of hyponatremia due to inappropriate antidiuretic hormone secretion: efficacy and safety analysis in a cohort study].” Nutricion hospitalaria (2025). PMID: 39873469 ↗
L2bCOHORTCited in: Management, Complications and Prognosis - [168]
Basan H, Bilginer Gürbüz B, Gürbüz F et al.. “Management of porphyria-like syndrome in tyrosinemia type 1.” Journal of pediatric endocrinology & metabolism : JPEM (2026). PMID: 41711566 ↗
L4CASE_REPORTCited in: Management - [169]
Gil Dos Santos S, Calheiros R, Oliveira J et al.. “Urea for Treatment of SIAD Induced Hyponatremia: Experience of an Oncology Center.” Clinical endocrinology (2026). PMID: 40993889 ↗
L5OTHERCited in: Management - [170]
Akgül YSS, Cengiz BE, Akın S. “Rapid-Onset SIADH Triggered by Combined Duloxetine and Levodopa Use in an Older Adult With Depression and Parkinsonism: A Previously Unreported Interaction.” International journal of psychiatry in medicine (2026). PMID: 40859822 ↗
L4CASE_REPORTCited in: Management - [171]
Courtney A, Joyce Tan LY, Elsheikh A et al.. “Characteristics, management and outcomes of patients with hyponatraemia presenting to an Irish tertiary hospital.” Endocrine connections (2025). PMID: 40029815 ↗
L5OTHERCited in: Management - [172]
Uchiyama M, Inoue T, Kojima D et al.. “Syndrome of inappropriate antidiuretic hormone secretion in a patient with colon cancer using CAPOX plus bevacizumab therapy: a case report.” Journal of pharmaceutical health care and sciences (2025). PMID: 40745570 ↗
L4CASE_REPORTCited in: Management - [173]
Wendt R, Fenves AZ, Geisler BP. “Use of Urea for the Syndrome of Inappropriate Secretion of Antidiuretic Hormone: A Systematic Review.” JAMA network open (2023). PMID: 37902751 ↗
L2aSR_OBSCited in: Complications and Prognosis - [174]
Zamanipoor Najafabadi AH, van der Meulen M, Priego Zurita AL et al.. “Starting point for benchmarking outcomes and reporting of pituitary adenoma surgery within the European Reference Network on Rare Endocrine Conditions (Endo-ERN): results from a meta-analysis and survey study.” Endocrine connections (2023). PMID: 36327151 ↗
L2aSR_OBSCited in: Complications and Prognosis - [175]
Mezzini G, Marasco S, Bertuccio A et al.. “Hyponatremia Related to Neurocritical Care: Focus on Diagnosis and Therapy: A Systematic Review.” Reviews on recent clinical trials (2023). PMID: 36503463 ↗
L2aSR_OBSCited in: Complications and Prognosis - [176]
Mussarat A, Stielper Z, Hayden C et al.. “Severe hyponatremia secondary to syndrome of inappropriate antidiuretic hormone (SIADH): A rare cause of takotsubo (stress) cardiomyopathy.” The American journal of the medical sciences (2025). PMID: 39168409 ↗
L4CASE_REPORTCited in: Complications and Prognosis - [177]
Martin-Grace J, Tomkins M, O'Reilly MW et al.. “Approach to the Patient: Hyponatremia and the Syndrome of Inappropriate Antidiuresis (SIAD).” The Journal of clinical endocrinology and metabolism (2022). PMID: 35511757 ↗
L5REVIEW_NARRATIVECited in: Complications and Prognosis - [178]
Koumpis E, Florentin M, Hatzimichael E et al.. “Hyponatremia in Patients with Hematologic Diseases.” Journal of clinical medicine (2020). PMID: 33228240 ↗
L5REVIEW_NARRATIVECited in: Complications and Prognosis - [179]
Frara S, Allora A, Castellino L et al.. “COVID-19 and the pituitary.” Pituitary (2021). PMID: 33939057 ↗
L5REVIEW_NARRATIVECited in: Complications and Prognosis - [180]
Pazos-Guerra M, Ruiz-Sánchez JG, Pérez-Candel X et al.. “Inappropriate therapy of euvolemic hyponatremia, the most frequent type of hyponatremia in SARS-CoV-2 infection, is associated with increased mortality in COVID-19 patients.” Frontiers in endocrinology (2023). PMID: 37560297 ↗
L5OTHERCited in: Complications and Prognosis - [181]
Decaux G. “Morbidity Associated with Chronic Hyponatremia.” Journal of clinical medicine (2023). PMID: 36769626 ↗
L5OTHERCited in: Complications and Prognosis - [182]
Yuen KCJ, Ajmal A, Correa R et al.. “Sodium Perturbations After Pituitary Surgery.” Neurosurgery clinics of North America (2019). PMID: 31471059 ↗
L5REVIEW_NARRATIVECited in: Special Populations - [183]
Baig MU, Madden K, Moody K. “Hyponatremia with Antidepressant: A Rare Side Effect from Duloxetine in a Child with Acute Leukemia.” Journal of palliative medicine (2022). PMID: 35537479 ↗
L4CASE_REPORTCited in: Special Populations - [184]
Sarikonda A, Rafi R, Schuessler C et al.. “Smartphone Applications for Remote Monitoring of Patients After Transsphenoidal Pituitary Surgery: A Narrative Review of Emerging Technologies.” World neurosurgery (2024). PMID: 39214293 ↗
L5REVIEW_NARRATIVECited in: Special Populations - [185]
Kim J, Scott-Miller R. “Anesthesia for Pituitary Surgery.” Otolaryngologic clinics of North America (2022). PMID: 35365315 ↗
L5REVIEW_NARRATIVECited in: Special Populations - [186]
Mercier JC, Titomanlio L, Basmaci R et al.. “Risks of severe hyponatremia in children receiving hypotonic fluids.” Archives de pediatrie : organe officiel de la Societe francaise de pediatrie (2020). PMID: 33028494 ↗
L5REVIEW_NARRATIVECited in: Special Populations - [187]
Li C, Zhu H, Zong X et al.. “Experience of trans-nasal endoscopic surgery for pituitary tumors in a single center in China: Surgical results in a cohort of 2032 patients, operated between 2006 and 2018.” Clinical neurology and neurosurgery (2020). PMID: 32905978 ↗
L5REVIEW_NARRATIVECited in: Special Populations - [188]
Moritz ML. “Syndrome of Inappropriate Antidiuresis.” Pediatric clinics of North America (2019). PMID: 30454744 ↗
L5REVIEW_NARRATIVECited in: Special Populations - [189]
Constanthin PE, Isidor N, De Seigneux S et al.. “Association between urinary oxytocin secretion and natriuresis after transsphenoidal pituitary surgery.” Journal of neurosurgery (2023). PMID: 37209066 ↗
L5OTHERCited in: Special Populations - [190]
Findlay MC, Drexler R, Khan M et al.. “A Multicenter, Propensity Score-Matched Assessment of Endoscopic Versus Microscopic Approaches in the Management of Pituitary Adenomas.” Neurosurgery (2023). PMID: 37057921 ↗
L5OTHERCited in: Special Populations - [191]
Lopez DC, Almeida JP, Momin AA et al.. “Triphasic response after endoscopic craniopharyngioma resection and its dependency on infundibular preservation or sacrifice.” Journal of neurosurgery (2023). PMID: 36738460 ↗
L5OTHERCited in: Special Populations - [192]
Snyder MH, Asuzu DT, Shaver DE et al.. “Routine postoperative fluid restriction to prevent syndrome of inappropriate antidiuretic hormone secretion after transsphenoidal resection of pituitary adenoma.” Journal of neurosurgery (2022). PMID: 34330096 ↗
L5OTHERCited in: Special Populations - [193]
Indirli R, Ferreira de Carvalho J, Cremaschi A et al.. “Tolvaptan in the Management of Acute Euvolemic Hyponatremia After Transsphenoidal Surgery: A Retrospective Single-Center Analysis.” Frontiers in endocrinology (2021). PMID: 34108941 ↗
L5OTHERCited in: Special Populations - [194]
Spasovski G, Vanholder R, Allolio B et al.. “Clinical practice guideline on diagnosis and treatment of hyponatraemia.” European journal of endocrinology (2014). PMID: 24569125 ↗
L1cGUIDELINECited in: Guidelines and Resources - [195]
Spasovski G, Vanholder R, Allolio B et al.. “Clinical practice guideline on diagnosis and treatment of hyponatraemia.” Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association (2014). PMID: 24569496 ↗
L1cGUIDELINECited in: Guidelines and Resources - [196]
Bennett BL, Hew-Butler T, Hoffman MD et al.. “Wilderness Medical Society practice guidelines for treatment of exercise-associated hyponatremia: 2014 update.” Wilderness & environmental medicine (2014). PMID: 25498260 ↗
L1cGUIDELINECited in: Guidelines and Resources - [197]
Runkle I, Villabona C, Navarro A et al.. “[The treament of hyponatremia secundary to the syndrome of inappropriate antidiuretic hormone secretion].” Medicina clinica (2013). PMID: 24169317 ↗
L1cGUIDELINECited in: Guidelines and Resources - [198]
Bennett BL, Hew-Butler T, Hoffman MD et al.. “Wilderness Medical Society practice guidelines for treatment of exercise-associated hyponatremia.” Wilderness & environmental medicine (2013). PMID: 23590928 ↗
L1cGUIDELINECited in: Guidelines and Resources - [199]
Lamas C, del Pozo C, Villabona C. “Clinical guidelines for management of diabetes insipidus and syndrome of inappropriate antidiuretic hormone secretion after pituitary surgery.” Endocrinologia y nutricion : organo de la Sociedad Espanola de Endocrinologia y Nutricion (2014). PMID: 24588923 ↗
L1cGUIDELINECited in: Guidelines and Resources